Updated Jun 29, 2026, 9:42 a.m. Published Jun 29, 2026, 7:03 a.m.
1 min read
Summary
BitMEX CEO Stephan Lutz, Chief Financial Officer Ina Steiner, and Chief Growth Officer Raphael Polansky are no longer with the company.BitMEX, which was co-founded in 2014 by Arthur Hayes, Ben Delo and Samuel Reed, has reportedly been looking for a buyer.BitMEX, the troubled cryptocurrency exchange reportedly looking for a buyer, has cleared out its executive team, losing CEO Stephan Lutz, CFO Ina Steiner, and Chief Growth Officer Raphael Polansky, CoinDesk has learned.
Stephan Lutz resigned from his role as CEO of BitMEX, a spokesperson for the exchange infomed CoinDesk.
The firm’s former global general counsel and chief operating officer, Peter Wilkinson, has taken over as CEO. The moves were highlighted in recent postings on LinkedIn.
Wilkinson, Lutz, Steiner and Polansky did not immediately respond to requests for comment.
The crypto exchange and derivatives trading platform was co-founded in 2014 by Arthur Hayes, Ben Delo and Samuel Reed. In 2020, BitMEX was alleged to have failed to implement adequate anti-money laundering measures in place, and later pleaded guilty to the charges. Hayes, Delo and Reed resigned shortly after the U.S. brought criminal charges.
BitMEX is presumably looking to streamline its costs and appear more attractive to prospective buyers, as an ongoing depression in digital asset prices weights on the crypto industry.
It was during the last crypto downturn in 2022 that Lutz took over as CEO from Alexander Hoeptner, who became CEO in early 2021, when Hayes and his co-founders stepped down.
The latest crypto winter has prompted numerous crypto and tech firms to shed staff.
CORRECT (June 29, 09:37 UTC): Clarifies that Stephan Lutz resigned from his role as CEO of BitMEX in second paragraph.
12345678910
The Evolution of the Crypto CEX Landscape: A Case Study on Binance
The Evolution of the Crypto CEX Landscape: A Case Study on Binance
Binance remains crypto’s leading exchange, expanding from spot and derivatives into RWAs, payments, savings, yield, and broader financial services.
8 minutes ago
Binance remains crypto’s leading exchange, expanding from spot and derivatives into RWAs, payments, savings, yield, and broader financial services.
Why it matters:
Binance remains crypto’s leading exchange, expanding from spot and derivatives into RWAs, payments, savings, yield, and broader financial services.
Not financial or tax advice. PANews content is strictly educational and informational and is not investment advice, financial advice, tax advice, legal advice, or a solicitation to buy or sell any digital asset, security, or financial product. Do your own research and consult qualified advisers.
Disclosure. PANews may publish sponsored content, partner content, advertisements, affiliate links, event promotions, and market commentary involving Web3 projects, service providers, or financial products. PANews personnel, contributors, or affiliates may hold digital assets or other interests related to covered topics. See our Terms of Service.
BitMEX co-founder Arthur Hayes purchased 6.16 million Synapse ($SYN) tokens worth approximately $2.2 million in a single transaction, according to on-chain analytics platform Lookonchain. The buy was flagged publicly roughly one hour after it was recorded on-chain.
The Trade and the Thesis The transaction was routed through FlowDesk, a Paris-based over-the-counter trading desk that facilitates large block trades away from public order books, with an implied entry price of around $0.36 per token based on the reported transaction size. The purchase came before Hayes publicly backed Hypercall, an options decentralised exchange connected to the Synapse ecosystem. Hayes framed the position around seeking asymmetric exposure within the Hyperliquid ecosystem, pointing to Hypercall as an options DEX with the potential to compete with Deribit.
That framing places SYN inside a derivatives narrative rather than a straightforward cross-chain infrastructure play, which is what Synapse was originally built around. Synapse functions as an interchain programming interface, allowing developers to build applications with native cross-chain capabilities, with SYN serving as its primary governance and utility token.
A Token Already Deep in a Rally Hayes was not buying into a quiet market. SYN had already surged more than 10 times in value over the course of June before the trade was flagged. Data from CoinGecko shows the token trading at around $0.3856 on June 29, representing a 122.90% gain over the prior seven days alone, with 24-hour trading volume approaching $95 million. With a circulating supply of around 220 million tokens, the market cap stood at roughly $84 million, making Hayes' $2.2 million position one of the more closely watched small-cap moves of the month.
The rally appeared to be driven more by broad DeFi risk-on sentiment and momentum buying than by a single fundamental catalyst. CoinMarketCap data noted SYN's multi-day surge was attributed to technicals rather than new project fundamentals, with the token rebounding from an all-time low of $0.027 set earlier in June.
The trade is consistent with Hayes' broader pattern of accumulating smaller, higher-beta assets during momentum cycles. On-chain records show he has made several significant DeFi token purchases in recent months, including Ethereum, ENA, and ETHFI.
Sources:
CryptoAdventure: Arthur Hayes Buys 6.16M SYN Tokens Worth $2.2M Through FlowDesk
CoinGecko: Synapse (SYN) Price and Market Data
**Editorial Note: This article cannot be responsibly published in any form.**
The central claim of this article — that BitMEX removed its CEO, CFO, and head of growth — has no verified basis in the research provided. The research explicitly states: “No verified reports exist of recent executive removals (2025-2026) at BitMEX” and identifies Stephan Lutz as actively serving as Group CEO into 2026.
Advertisement
Because the foundational premise of the article is unverified, every paragraph built upon it — including the market analysis, trader guidance, and competitive commentary — is also unsupported. Pruning individual paragraphs is not possible when the core news event itself cannot be confirmed.
The only facts in the research that are verified are:
– Arthur Hayes stepped down as CEO in October 2020 following U.S. criminal charges related to Bank Secrecy Act violations.
– Alexander Höptner resigned as CEO in October 2022.
– Stephan Lutz became interim CEO following Höptner’s departure and held the Group CEO role into 2026.
– BitMEX pioneered the perpetual swap contract.
Publishing this article would risk spreading misinformation about a named company and its named executives. The article should be withheld pending confirmation of the reported executive removals from verified sources.
Disclosure: This article was edited by Editorial Team. For more information on how we create and review content, see our Editorial Policy.
Intercontinental Exchange plans to launch futures products linked to monetary policy decisions and energy reserves.
Intercontinental Exchange (ICE), parent company of the New York Stock Exchange (NYSE), is planning to launch new futures contracts tied to global monetary policy decisions and U.S. natural gas inventories, aiming to provide investors with another avenue to hedge against risks from economic events. According to company executives, ICE plans to roll out futures products based on interest rate decisions by the U.S. Federal Reserve, European Central Bank (ECB) and Bank of England (BoE). Subject to regulatory approval, these economic indicator-based products are scheduled to launch on August 10. The move will allow investors to trade or hedge around policy meetings of the three major global central banks and weekly U.S. Energy Information Administration (EIA) natural gas inventory releases.
16 minutes ago
Suspected shell accounts operating across multiple scattered addresses have laid in wait for Micron Technology, opening combined long positions in MU totaling 10 million.
According to Hyperinsight monitoring, four whales opened long positions on Micron Technology (MU) on Hyperliquid today, while only one large trader established a short position, reflecting an overall bullish bias among large market funds. Three of the addresses completed their positions almost simultaneously in the afternoon. On-chain data shows these three addresses have highly correlated position structures, trading rhythms, and funding sources, and are suspected to belong to the same trading entity splitting positions across multiple addresses. All three addresses boast a historical win rate of over 60%, are known for their conservative trading style, and maintain strong drawdown control. Since June alone, they have accumulated realized profits of approximately $1.8 million. Additionally, all three received large capital injections in June; two are new active wallets over the past month, with highly consistent fund deployment and trading behavior. Currently, the average entry price of MU long positions for the three addresses (0xf8a, 0xd5c, 0xf2d) is around $1,156, with a recent liquidation price of roughly $938. They hold a total of 9,027 MU contracts, with a notional position size of about $10.3 million. As of press time, affected by MU’s short-term pullback, this batch of positions has recorded an unrealized floating loss of approximately 15%. HyperInsight Bot is now live. Add @HyperInsightBot to your Telegram group, set it as an admin (enable message sending permission), and it will automatically sync on-chain news.
16 minutes ago
Iran's Deputy Foreign Minister: No Iran-US technical talks are scheduled for this week.
According to Iranian sources on the 29th, Iranian Deputy Foreign Minister Garibabadi stated that there are currently no arrangements to hold technical talks on a ceasefire memorandum of understanding (MoU) this week. Garibabadi emphasized in an interview that while consultations with parties including Qatar are proceeding as planned, reports that a working group technical meeting will be held in Doha remain unconfirmed. Once relevant conditions are met and all parties agree on the date and venue of the talks, Iran will participate in the first round of technical talks under the framework of the designated working group, with the relevant consultations currently being conducted through intermediary countries.
16 minutes ago
Melius Research assigns Western Digital a "Buy" rating, with a target price of $105.
Melius Research initiates coverage on Western Digital (WDC.O), assigning a "Buy" rating with a target price of $105.
16 minutes ago
Serenity: The key inflection point for the development of the robotics industry appears to have arrived.
Serenity published a report stating that General Motors (GM) has laid off roughly 1,000 employees and replaced some positions with around 50 robots. At the same time, there are reports that GM is in talks with NVIDIA over factory robot collaborations. This is regarded as an important signal that the robotics industry is moving toward large-scale commercial adoption, indicating that automation is expected to boost corporate operational efficiency and improve profit margins, especially in labor-intensive sectors such as automotive manufacturing and warehousing logistics. Serenity believes that robot and humanoid robot technologies have largely matured and are currently in the early phase of large-scale rollout. Although large enterprises generally categorize them as "auxiliary robots", their core goal remains replacing certain manual roles with automation, cutting labor costs including salaries and insurance, enabling round-the-clock operations, and enhancing profitability. While the widespread adoption of robots may bring employment pressure, the key inflection point for the industry’s development seems to have arrived.
16 minutes ago
JPMorgan analysts raise target levels for European stocks.
Amid the Iran-related conflict that has battered European stock markets, JPMorgan analyst Mislav Matejka expects the selloff to be temporary. Now, he has doubled down on his bullish stance, emerging as the most optimistic bull among forecasters tracked by Bloomberg. Matejka and his team raised their year-end target for the Euro Stoxx 600 index from 630 to 680 points, implying roughly 7% upside from current levels. This new forecast surpasses the previous highest estimate of 670 points set by Barclays and HSBC earlier this month. The strategists wrote in a report: "After three years of stagnant growth, corporate earnings in the eurozone are accelerating this year." They project earnings per share (EPS) growth of 18% and 12% for 2026 and 2027, respectively. "If the market rally broadens in the second half of the year, European stocks could once again become a highly attractive investment."
A major shakeup has taken place at cryptocurrency exchange and derivatives platform BitMEX. CEO Stephan Lutz, Chief Financial Officer Ina Steiner, and Chief Growth Officer Raphael Polansky have all stepped down from their roles. In their place, Peter Wilkinson, who previously served as BitMEX’s Global General Counsel, has now assumed the position of CEO.
Leadership overhaul at BitMEXThe recent changes are now reflected in the company’s executives’ professional profiles. Before becoming CEO, Peter Wilkinson held dual responsibilities as Global General Counsel and Head of Operations at BitMEX. Founded in 2014, BitMEX has long established itself as a major player in the crypto derivatives market, becoming synonymous with digital asset trading for a decade.
As Stephan Lutz, Ina Steiner, and Raphael Polansky leave BitMEX, Peter Wilkinson becomes the new chief executive.
None of the outgoing executives—Lutz, Steiner, or Polansky—have responded to requests for comment regarding the departures. BitMEX has yet to release a formal statement clarifying whether this management reshuffle is part of a wider organizational restructuring plan aimed at the company’s long-term future.
Rumors of a sale and BitMEX’s legal historyRecent months have been rife with speculation that BitMEX is actively seeking potential buyers. The platform, originally established by Arthur Hayes, Ben Delo, and Samuel Reed, staked its reputation on advanced derivatives trading but also became known for run-ins with regulatory authorities.
In 2020, U.S. authorities accused BitMEX of failing to incorporate sufficient anti-money laundering controls. This led the company to eventually admit guilt in a drawn-out legal process. Following civil and criminal proceedings in the U.S., Hayes, Delo, and Reed all resigned from their executive roles.
The company is thought to be streamlining its costs in a bid to make itself more attractive to potential buyers.
Industrywide restructuring under market pressureWeak digital asset prices continue to exert pressure on companies throughout the crypto sector. The latest departures at BitMEX are widely seen as part of efforts to reduce overhead and simplify operations—in line with a broader industry trend fueled by challenging market conditions.
Stephan Lutz was only appointed CEO in 2022 during a period of sharp market decline, stepping in after Alexander Hoeptner’s tenure. Hoeptner himself succeeded the founders in early 2021, following the initial wave of executive exits in the aftermath of legal troubles.
The latest phase of management turnover at BitMEX follows a broader move across the industry, as crypto exchanges and digital asset companies respond to turbulent markets by implementing staff cuts and making significant leadership changes.
Disclaimer: The information contained in this article does not constitute investment advice. Investors should be aware that cryptocurrencies carry high volatility and therefore risk, and should conduct their own research.
, /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Badger Meter, Inc. ("Badger" or "the Company") (NYSE: BMI) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Shareholders who purchased shares of BMI during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments. Appointment as lead plaintiff is not required to partake in any recovery.
CLASS PERIOD: April 18, 2024 to April 16, 2026
DEADLINE: August 3, 2026
CASE DETAILS: According to the Complaint, the Company made false and misleading statements to the market. Badger Meter claimed "secular growth drivers" and "solid operating execution" were fueling its financial performance. Despite its positive comments, the Company's performance was partially based on pulling customer orders forward. Based on these facts, Badger Meter's public statements were false and materially misleading throughout the class period.
If you are a shareholder who suffered a loss, contact us to participate.
WHY DJS LAW GROUP? DJS Law Group's primary focus is to enhance investor return through balanced counseling and aggressive advocacy. We specialize in securities class actions, corporate governance litigation, and domestic/international M&A appraisals. Our clients are some of the largest and most sophisticated hedge funds and alternative asset managers in the world. The litigation claims of our clients are extraordinarily valuable assets that demand respect, focus, and results.
Join the case to recover your losses.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
CONTACT:
David J. Schwartz
DJS Law Group
274 White Plains Road, Suite 1
Eastchester, NY 10709
Phone: 914-206-9742
Email: [email protected]
PANews June 29 news, according to Cailian Press, all three major indices closed higher, the ChiNext Index rebounded after dipping, and the STAR 50 Index surged 4.61%. Total trading volume across the Shanghai and Shenzhen markets was 3.52 trillion yuan, shrinking by 34.7 billion yuan from the previous trading day. On the market, hot spots rotated rapidly, and more than 2,900 stocks fell across the board. By sector, the semiconductor equipment sector strengthened, with Jinhaitong, Huaya Intelligence, Baicheng Co., Ltd., and Huahai Qingke hitting limit up. The electronic specialty gas concept was active in the afternoon, with Haohua Technology, Kaimeite Gases, and Guanggang Gas hitting limit up. The pharmaceutical sector exploded, with more than twenty constituent stocks hitting limit up; Hainan Haiyao achieved 3 boards in 5 days, and Wanbang Pharmaceutical, Tailong Pharmaceutical, and Teyi Pharmaceutical hit limit up. The controllable nuclear fusion concept was active, with Baili Electric, Lianchuang Optoelectronics, CNNC Science & Technology, and China Nuclear Engineering hitting limit up. The retail concept oscillated and pushed higher, with Ningbo Zhongbai achieving 2 boards in 3 days and Zhongbai Group hitting limit up. On the downside, the fiber optics concept fell intraday, and Changyingtong hit a 20% daily limit down. The glass fiber concept fluctuated and adjusted, with Honghe Technology and Shandong Fiberglass falling by the daily limit. At the close, the Shanghai Composite Index rose 1.16%, the Shenzhen Component Index rose 0.19%, and the ChiNext Index rose 0.54%.
LOS ANGELES--(BUSINESS WIRE)--Korn Ferry (NYSE: KFY), a global organizational consulting firm, today announced that it has entered into a definitive agreement with OMERS Private Equity to acquire UK-headquartered AMS, which will create a global leader in talent and organizational consulting.
The combination will bring together two highly complementary organizations across geographies and industries with a shared commitment to drive business performance. Following completion, the collective firm will have more than 16,000 colleagues placing a professional in a job approximately every 90 seconds.
“By bringing AMS into the Korn Ferry family, we are expanding our ability to help clients solve their most critical organizational challenges,” said Gary D. Burnison, CEO, Korn Ferry. “Despite all of the technological innovations of yesterday, today and tomorrow, the real driver of organizational success is people. And with our AMS colleagues we will be stronger together than apart. Over almost 20 years I have watched AMS grow and evolve, with deep admiration and respect. I am convinced that the culture and values of both companies are completely aligned. And it all starts with people. This is indeed a significant milestone for Korn Ferry and I am excited about the future that we will shape together.”
The transaction will combine Korn Ferry’s expertise across Search, Talent & Organizational Solutions, and Workforce Solutions with AMS’s highly regarded expertise in Recruitment Process Outsourcing (RPO), Early Careers and Campus Recruiting, Contingent Workforce Solutions, Consulting, and Skills Creation.
“At AMS we connect organizations with the people who advance their vision and deliver their purpose—powering industries, achieving results and shaping futures,” said Rosaleen Blair, Founder and Chair of AMS. “In Korn Ferry we have a like-minded partner that shares the same beliefs and embraces the same values.” Following the consummation of the transaction, Rosaleen Blair will continue in a Chair role.
“Combining AMS with Korn Ferry will create new opportunities for our clients, our teams, and accelerate our ability to shape the future of work,” said Gordon Stuart, CEO of AMS.
“AMS has made incredible progress over the course of our ownership,” said Michael Block, Head of Private Capital, OMERS. “We have supported the company as it has expanded its capabilities, strengthened its client relationships and focused on the people and organizations it serves. Korn Ferry is a strong strategic fit for AMS as it enters its next chapter.”
Founded by Rosaleen Blair in 1996, AMS serves many of the world’s leading organizations across financial services, technology, healthcare, life sciences, consumer, industrial, and public sector markets. Its operations span more than 120 countries, including a well-established presence throughout Europe and Asia.
Drawing on the totality and strength of both firms—and leveraging combined expertise and relationships across geographies, the combined company will create more sustainable opportunities at scale.
Terms of the Acquisition Agreement
Under the terms of the acquisition agreement, Korn Ferry has agreed to acquire AMS for an aggregate purchase price of approximately £850 million (approximately $1.1 billion), consisting of (i) approximately £659 million (approximately $881 million) in cash and (ii) approximately £191 million (approximately $255 million) in Korn Ferry common stock.1
Korn Ferry expects to fund the cash portion of the transaction consideration with approximately $300 million of cash on hand and the remaining approximately $581 million of cash consideration with borrowings under Korn Ferry’s existing revolver. Additionally, Korn Ferry will issue approximately 3.6 million shares2, subject to a 15% collar at the closing.
On a current annual run-rate basis, AMS is generating approximately $650 million of Fee Revenue and $100 million of Adjusted EBITDA.3 Assuming no adverse change in the economic environment, Korn Ferry estimates that the run-rate Adjusted EBITDA3 contribution within a year following the closing of the acquisition will be approximately $140 million.
The consummation of the transaction is subject to receipt of regulatory clearances and is expected to close in Korn Ferry’s 2nd fiscal quarter of FY’27. The transaction is expected to be immediately accretive to earnings per share in the first full year after adjusting for restructuring and integration and transaction costs.
AMS’s long-term contracts will add more than $1.5 billion in estimated fees remaining under existing contracts, providing greater revenue visibility and enhancing the Company’s ability to provide scalable, data-driven talent strategies across geographies and industries.
Additional details regarding the transaction will be discussed during a conference call with investors on Monday, June 29 at 8:30 a.m. EDT. The call will be webcast and available online at www.kornferry.com under Investor Relations, News & Events.
About Korn Ferry
Korn Ferry is a global consulting firm that powers performance. We unlock the potential in your people and unleash transformation across your business—synchronizing strategy, operations, and talent to accelerate performance, fuel growth, and inspire a legacy of change. That’s why the world’s most forward-thinking companies across every major industry turn to us—for a shared commitment to lasting impact and the bold ambition to Be More Than.
As the Official Talent & Organizational Consulting Partner of LA28, Korn Ferry is powering the nearly 5,000 people who power the Olympic Games—bringing in the right talent, building strong leaders, and shaping the structure and culture that will deliver an unforgettable experience for the world.
About AMS
We are people experts.
Our 8,000 colleagues power talent acquisition and consulting strategies that deliver results for leading organizations across 120 countries.
We partner with our clients to help re-define a new era of talent, driven by people, process, data and technology, enabling them to attract and retain the talent they need to achieve their vision.
Our core areas of service include: Recruitment Process Outsourcing (RPO), Early Careers and Campus Recruiting, Contingent Workforce Solutions, Consulting and Skills Creation, which are amplified by digital capability and strategic technology partnerships.
We call this...People powered partnership.
Forward-Looking Statements
Statements in this press release and our conference call include “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995 concerning the transaction. Forward-looking statements may be identified by the use of words such as “anticipate,” “believe,” “expect,” “estimate,” “may,” “plan,” “outlook,” “project,” “will” or other similar expressions. Such forward-looking statements include, but are not limited to, statements relating to the USD converted purchase price, the number of shares of Korn Ferry stock to be issued in the transaction, the timing of the transaction, the expected benefits of the transaction, including the global leadership position of the combined company, the combined company’s expanded capabilities, transaction synergies, future financial and operating results, and the combined company’s plans, objectives and expectations. A number of factors could cause actual results or outcomes to differ materially from those indicated by such forward-looking statements. Such risks and uncertainties, many of which are outside of the control of Korn Ferry, include, but are not limited to: (1) the occurrence of any event or change that could give rise to the termination of the acquisition agreement; (2) the inability to timely complete or complete at all the transaction; (3) delays in obtaining or the inability to obtain, necessary regulatory approvals; (4) the risk that the transaction disrupts current plans and operations of Korn Ferry and/or AMS; (5) the ability to successfully integrate the operations and employees of AMS into Korn Ferry; (6) the ability to recognize the anticipated benefits of the transaction which may be affected by, among other things, the ability of Korn Ferry and AMS (prior to the closing) and the combined company (following the closing) to maintain relationships with clients and suppliers and retain key employees; (7) currency exchange rates; (8) fluctuations in Korn Ferry’s stock price; (9) costs related to the transaction; (10) the outcome of any legal proceedings that may be instituted against Korn Ferry or AMS or their respective affiliates following announcement of the transaction; (11) the possibility that Korn Ferry or AMS may be adversely affected by economic, business, and/or competitive factors; and (12) other risks and uncertainties indicated from time to time in filings with the SEC by Korn Ferry. Korn Ferry undertakes no obligation to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise.
No Offer or Solicitation
This communication is not intended to and shall not constitute an offer to sell or the solicitation of an offer to sell or the solicitation of an offer to buy any securities.
LOS ANGELES--(BUSINESS WIRE)--Korn Ferry (NYSE: KFY) will host an investor call starting at 8:30 a.m. EDT today to discuss the acquisition of AMS. The conference call will be accessible through live webcast. Interested investors and other individuals can access the live audio webcast here or through the company’s homepage www.kornferry.com under Investor Relations, News & Events. A replay of the webcast will be archived on the company’s Investor Relations website and is expected to be available after 10:30 a.m. EDT on Monday, June 29, 2026 through 10:30 a.m. EDT Wednesday, July 29, 2026.
Please contact Investor Relations by email: [email protected] with any questions.
About Korn Ferry
Korn Ferry is a global consulting firm that powers performance. We unlock the potential in your people and unleash transformation across your business—synchronizing strategy, operations, and talent to accelerate performance, fuel growth, and inspire a legacy of change. That’s why the world’s most forward-thinking companies across every major industry turn to us—for a shared commitment to lasting impact and the bold ambition to Be More Than.
As the Official Talent & Organizational Consulting Partner of LA28, Korn Ferry is powering the nearly 5,000 people who power the Olympic Games—bringing in the right talent, building strong leaders, and shaping the structure and culture that will deliver an unforgettable experience for the world.
Sprout Social (SPT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Key Takeaways ASML shares currently hover around $1,841, within a 52-week trading band of $683.48 to $1,959.04, commanding a $724 billion market valuation The company’s order backlog stays robust as semiconductor manufacturers reserve EUV machinery years ahead, guaranteeing revenue visibility Revenue from installed base operations reached €2.49 billion in Q1 2026, climbing from €2.13 billion in the preceding quarter Management elevated full-year 2026 sales outlook to €36–€40 billion, while earnings per share are projected to surge 33% in the coming year Analyst consensus leans Moderate Buy with a mean price objective of $1,772.62; Bank of America maintained its Buy stance and increased its target ASML began Friday’s session at $1,841.18. This represents a dramatic recovery from the 52-week floor of $683.48, and approaches the ceiling of $1,959.04. Following such a substantial appreciation, investors naturally wonder: does meaningful upside remain?
ASML Holding N.V., ASML
The current valuation demands attention. ASML commands approximately 49.9x this year’s anticipated EPS of just under $36. This multiple significantly exceeds its historical average in the mid-30s range. For typical corporations, such pricing would trigger caution.
Yet ASML operates in a category of its own.
The Dutch company maintains an uncontested monopoly on Extreme Ultraviolet lithography equipment — the critical machinery enabling cutting-edge semiconductor production. Manufacturing 2-nanometer chips is impossible without this technology. No competing suppliers exist.
Each unit commands a price exceeding $350 million and requires months for assembly, precision calibration, and delivery. Customers don’t simply submit purchase orders — they reserve manufacturing capacity years into the future. This represents far more than a healthy sales funnel. It constitutes structural market control.
Order Backlog and Service Revenue Drive Fundamentals Q1 2026 net revenue totaled €8.77 billion, representing a decline from Q4 2025’s €9.72 billion. At first glance, this suggests weakening momentum. The reality differs considerably.
ASML’s quarterly revenue fluctuates based on delivery schedules rather than underlying demand. Every system the company manufactures already has a committed buyer. The quarter-over-quarter decrease reflects production capacity constraints, not softening customer appetite.
The more revealing metric comes from installed base management. This revenue category — encompassing maintenance and enhancement of existing deployed systems — registered €2.49 billion in Q1, advancing from €2.13 billion the prior quarter. It delivers predictable, margin-rich, and expanding cash flows.
Executives lifted full-year 2026 guidance to a revenue corridor of €36 billion to €40 billion. The latter half of the year should show acceleration, powered by increasing system deliveries.
TSMC, Intel, and Samsung are all expanding fabrication facilities to satisfy AI infrastructure requirements. These facilities require ASML’s equipment. Hyperscaler capital spending is forecast to nearly double from $427 billion in 2025 to beyond $860 billion by 2027.
Profit Margin Improvement Represents the Upcoming Driver EPS consensus forecasts indicate 33% expansion next year. This figure anchors the bullish investment thesis.
The route to that outcome flows through margin enhancement. ASML is shifting from limited-volume, early-phase production of its latest systems — including the high-margin High-NA EUV platform and the NXE:3800 series — toward standardized, volume-scale manufacturing. Fixed expense allocation improves across larger unit counts. Gross margins should progress toward management’s 2030 objective of 56%–60%.
One notable risk persists. China continues to represent approximately 19% of ASML’s revenue, and export limitations remain an active concern. Dutch government representatives are reportedly advocating against stricter restrictions on equipment sales to Chinese customers. Any intensification on this front could constrain sales.
Decker Retirement Planning recently established a fresh $4.23 million stake in ASML. Dimensional Fund Advisors maintains ownership exceeding 990,000 shares. Institutional holdings comprise 26.07% of outstanding equity.
Goldman Sachs, Citigroup, Morgan Stanley, and Deutsche Bank all maintain Buy ratings or equivalents. Bank of America elevated its price objective citing improved earnings projections for 2027 and 2028.
The consensus mean target stands at $1,772.62, though an alternative analyst cohort establishes it at $2,019 — suggesting approximately 12.5% appreciation potential from present levels.
Here are three stocks with buy ranks and strong growth characteristics for investors to consider today, June 29:
Celestica Inc. (CLS - Free Report) : This supply chain solutions provider carries a Zacks Rank #1, and has witnessed the Zacks Consensus Estimate for its current year earnings increasing 13.7% over the last 60 days.
Celestica has a PEG ratio of 0.73 compared with 0.96 for the industry. The company possesses a Growth Score of B.
Cboe Global Markets, Inc. (CBOE - Free Report) : This derivatives and securities exchange network carriesa Zacks Rank #1, and has witnessed the Zacks Consensus Estimate for its current year earnings increasing 7.3% over the last 60 days.
Cboe Global Markets has a PEG ratio of 1.08 compared with 1.65 for the industry. The company possesses a Growth Score of A.
Centene Corporation (CNC - Free Report) : This managed care company carriesa Zacks Rank #1, and has witnessed the Zacks Consensus Estimate for its current year earnings increasing 12.7% over the last 60 days.
Centene has a PEG ratio of 0.51 compared with 1.13 for the industry. The company possesses a Growth Score of B.
See the full list of top-ranked stocks here.
Learn more about the Growth score and how it is calculated here.
Shake Shack remains a buy amid a ~60% stock decline YoY, while its long-term growth and re-rating potential are intact. Recent guidance cuts reflect macroeconomic headwinds, with Q2 revenue and margin expectations lowered and near-term volatility being likely. SHAK's asset-light model, strong balance sheet, and digital initiatives support ongoing expansion and improved guest engagement.
GE Vernova Inc. is positioned at the tightest bottleneck in the AI-driven power infrastructure cycle, with unmatched exposure to gas turbines and transformers. GEV's Q1 2026 results highlight surging demand: 71% YoY order growth, a record $163 billion backlog, and strong pricing power with hardware capacity reserved through 2030. Recent Prolec GE acquisition and electrification orders ($7.1B in Q1 2026) reinforce GEV's strategic grid position and long-term growth visibility.
, /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against POET Technologies Inc. ("POET" or "the Company") (NASDAQ: POET) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Shareholders who purchased shares of POET during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments. Appointment as lead plaintiff is not required to partake in any recovery.
CLASS PERIOD: April 1, 2026 to April 27, 2026
DEADLINE: June 29, 2026
CASE DETAILS: According to the Complaint, the Company made false and misleading statements to the market. The likelihood of POET being declared a passive foreign investment company ("PFIC") led it to misrepresenting its tax status. Based on these facts, POET's public statements were false and materially misleading throughout the class period.
If you are a shareholder who suffered a loss, contact us to participate.
WHY DJS LAW GROUP? DJS Law Group's primary focus is to enhance investor return through balanced counseling and aggressive advocacy. We specialize in securities class actions, corporate governance litigation, and domestic/international M&A appraisals. Our clients are some of the largest and most sophisticated hedge funds and alternative asset managers in the world. The litigation claims of our clients are extraordinarily valuable assets that demand respect, focus, and results.
Join the case to recover your losses.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
CONTACT:
David J. Schwartz
DJS Law Group
274 White Plains Road, Suite 1
Eastchester, NY 10709
Phone: 914-206-9742
Email: [email protected]
, /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Futu Holdings Limited ("Futu" or "the Company") (NASDAQ: FUTU) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Shareholders who purchased shares of FUTU during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments. Appointment as lead plaintiff is not required to partake in any recovery.
CLASS PERIOD: May 24, 2023 to May 27, 2026
DEADLINE: August 25, 2026
CASE DETAILS: According to the Complaint, the Company made false and misleading statements to the market. Futu operated in China without licensing and approval from the China Securities Regulatory Commission ("CSRC"), putting it at risk of regulatory action in the country. Based on these facts, Futus public statements were false and materially misleading throughout the class period.
If you are a shareholder who suffered a loss, contact us to participate.
WHY DJS LAW GROUP? DJS Law Group's primary focus is to enhance investor return through balanced counseling and aggressive advocacy. We specialize in securities class actions, corporate governance litigation, and domestic/international M&A appraisals. Our clients are some of the largest and most sophisticated hedge funds and alternative asset managers in the world. The litigation claims of our clients are extraordinarily valuable assets that demand respect, focus, and results.
Join the case to recover your losses.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
CONTACT:
David J. Schwartz
DJS Law Group
274 White Plains Road, Suite 1
Eastchester, NY 10709
Phone: 914-206-9742
Email: [email protected]
, /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Futu Holdings Limited ("Futu" or "the Company") (NASDAQ: FUTU) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Investors who purchased the Company's securities between May 24, 2023 and May 27, 2026, inclusive (the "Class Period"), are encouraged to contact the firm before August 25, 2026.
If you are a shareholder who suffered a loss, click here to participate.
We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at [email protected].
The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.
According to the Complaint, the Company made false and misleading statements to the market. Futu failed to maintain compliance with the China Securities Regulatory Commission ("CSRC"). The Company was likely to face regulatory action in China due to its failure to comply with CSRC regulations. Based on these facts, the Company's public statements were false and materially misleading throughout the class period. When the market learned the truth about Futu, investors suffered damages.
Join the case to recover your losses
The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
CONTACT:
The Schall Law Firm
Brian Schall, Esq.,
www.schallfirm.com
Office: 310-301-3335
[email protected]
FUTU Investors Have Opportunity to Lead Futu Holdings Limited Securities Fraud Lawsuit with the Schall Law Firm PR Newswire
LOS ANGELES, June 29, 2026
, /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Futu Holdings Limited ("Futu" or "the Company") (NASDAQ: FUTU) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Investors who purchased the Company's securities between May 24, 2023 and May 27, 2026, inclusive (the "Class Period"), are encouraged to contact the firm before August 25, 2026.
If you are a shareholder who suffered a loss, click here to participate.
We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at [email protected].
The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.
According to the Complaint, the Company made false and misleading statements to the market. Futu failed to maintain compliance with the China Securities Regulatory Commission ("CSRC"). The Company was likely to face regulatory action in China due to its failure to comply with CSRC regulations. Based on these facts, the Company's public statements were false and materially misleading throughout the class period. When the market learned the truth about Futu, investors suffered damages.
Join the case to recover your losses
The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
CONTACT:
The Schall Law Firm
Brian Schall, Esq.,
www.schallfirm.com
Office: 310-301-3335 [email protected]
View original content to download multimedia:https://www.prnewswire.com/news-releases/futu-investors-have-opportunity-to-lead-futu-holdings-limited-securities-fraud-lawsuit-with-the-schall-law-firm-302812902.html
Futu Holdings Limited Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - FUTU PR Newswire
LOS ANGELES, June 29, 2026
, /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Futu Holdings Limited ("Futu" or "the Company") (NASDAQ: FUTU) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Shareholders who purchased shares of FUTU during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments. Appointment as lead plaintiff is not required to partake in any recovery.
CLASS PERIOD: May 24, 2023 to May 27, 2026
DEADLINE: August 25, 2026
CASE DETAILS: According to the Complaint, the Company made false and misleading statements to the market. Futu operated in China without licensing and approval from the China Securities Regulatory Commission ("CSRC"), putting it at risk of regulatory action in the country. Based on these facts, Futus public statements were false and materially misleading throughout the class period.
If you are a shareholder who suffered a loss, contact us to participate.
WHY DJS LAW GROUP? DJS Law Group's primary focus is to enhance investor return through balanced counseling and aggressive advocacy. We specialize in securities class actions, corporate governance litigation, and domestic/international M&A appraisals. Our clients are some of the largest and most sophisticated hedge funds and alternative asset managers in the world. The litigation claims of our clients are extraordinarily valuable assets that demand respect, focus, and results.
Join the case to recover your losses.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
CONTACT:
David J. Schwartz
DJS Law Group
274 White Plains Road, Suite 1
Eastchester, NY 10709
Phone: 914-206-9742
Email: [email protected]
View original content:https://www.prnewswire.com/news-releases/futu-holdings-limited-sued-for-securities-law-violations---contact-the-djs-law-group-to-discuss-your-rights--futu-302812903.html
SpaceX stock NASDAQ:SPCX has had a wild first few weeks as a public company.
The shares, priced at $135 in the company’s record June 12 IPO, surged to an intraday high of $225.64 by June 16, and then slid to around $153 by June 27.
That is a drop of roughly 32% from the peak, even though the stock is still above its IPO price.
The first thing investors need to separate is price from value.
A stock falling 32% can feel cheap because it is no longer trading at its recent high. But that does not automatically mean the valuation makes sense.
As per market data, SpaceX was still trading at about 107 times 2025 sales after the pullback.
That is an extreme multiple, even by the standards of AI and space-infrastructure stocks. Nvidia, by comparison, recently traded at roughly 21 times sales.
The financial picture also shows why some investors are cautious. SpaceX lost $4.9 billion in 2025, even as revenue reached $18.7 billion.
The business is growing fast, led by Starlink and its launch dominance, but it is not yet profitable at the group level.
That is the core bear-case argument. SpaceX may be one of the most exciting companies ever to hit the public market, but the stock is still priced for years of huge execution wins.
Morningstar’s Nicolas Owens has one of the clearest cautious views on the stock.
The analyst gave the company credit for its launch cost advantage, Starlink’s scale and the possibility of orbital AI infrastructure. It still comes out well below where the market is trading the stock.
Owens wrote that SpaceX shares are likely to look “overvalued in almost any scenario, at least in the near term”.
Morningstar also said long-term investors may get “more margin of safety” later, when lockups expire and more shares become available for sale.
That lockup point is important as SpaceX has a small public float, meaning only a limited portion of its shares can currently trade.
When supply is tight and demand is intense, prices can swing violently.
As more insider and employee shares become eligible for sale later this year, the market will get a better test of where natural demand really sits.
None of this means SpaceX is an empty story.
The company dominates the global space launch. As per analyst estimates, SpaceX launched 83% of the mass sent to orbit from Earth in 2025, nearly 10 times more than its nearest competitor.
Starlink is another pillar of the bull case. The satellite broadband business has become SpaceX’s clearest path to near-term cash generation, helped by its ability to launch satellites at in-house cost.
Starlink is expected to remain the company’s main cash-flow engine in the medium term, the analysts noted.
Index demand may also support the shares in the short term as SpaceX is being added to Russell indexes and will join the Nasdaq 100 on July 7, forcing passive funds that track those benchmarks to buy the stock.
Even after its sharp pullback, Space Exploration Technologies' (SPCX +0.15%) market cap still hovers around $2 trillion. That's an astronomical (no pun intended) valuation for a company that generated revenue of $18.7 billion last year and posted a loss of nearly $5 billion.
Could SpaceX double anytime soon? It's highly unlikely. Maybe over a long period of time, the company will open up exciting new markets that could lead to its share price gaining 100% or more. However, its premium pricing and the prospects of near-term insider selling after the lockup period expires present significant hurdles to the stock doubling over the next two or three years.
Investors who want explosive upside don't need to bet on science fiction valuations. Here are three stocks that have realistic paths to doubling relatively quickly.
Image source: Getty Images.
1. ADMA Biologics Unlike SpaceX, ADMA Biologics (ADMA +0.34%) is already profitable. And its earnings are growing. The company posted net income of $407 million in the first quarter, up 22% year over year.
ADMA markets three approved products, all plasma-derived immunoglobulin (IG) therapies. Asceniv is its flagship product, generating roughly 86% of total revenue. It was approved by the U.S. Food and Drug Administration (FDA) in 2019 for treating primary humoral immunodeficiency, a group of genetic disorders in which the body's immune system can't make enough antibodies, called immunoglobulins, to defend against infections.
Today's Change
(
0.34
%) $
0.03
Current Price
$
8.75
The consensus analysts' 12-month price target for this biotech stock is almost exactly double the current share price. Raymond James (RJF 0.01%) recently initiated coverage of ADMA Biologics with a buy recommendation and a price target that implies potential upside of around 140%.
What's behind Wall Street's optimism about ADMA? For one thing, the company has captured only around 4% of its total addressable market so far. That market is expected to grow at a compound annual rate of 10% through 2033. ADMA has also developed technology that delivers IG production yields 20% or more higher with the same quantities of plasma, which should boost both revenue and earnings.
2. EyePoint Pharmaceuticals EyePoint Pharmaceuticals (EYPT 0.36%) and SpaceX share at least two things in common. Both stocks are up around the same percentage year to date. Both companies are losing money. But EyePoint has a better excuse for its lack of profitability: it doesn't yet have an approved product.
That could change soon. EyePoint expects to report top-line results from two late-stage clinical studies evaluating Duravyu for the treatment of wet age-related macular degeneration (AMD) any day now (the company told investors the trials are "on track for data readouts beginning mid-year"). Enrollment in another Phase 3 study of the drug for the treatment of diabetic macular edema (DME) should wrap up in the third quarter of 2026.
Today's Change
(
-0.36
%) $
-0.05
Current Price
$
13.66
Wet AMD and DME represent a combined global market opportunity of over $15 billion. These markets are currently dominated by three drugs: Bayer's (BAYRY +1.06%) and Regeneron's (REGN +2.06%) Eylea, Roche's (RHHBY 0.23%) and Novartis' (NVS +0.13%) Lucentis, and Roche's Vabysmo. EyePoint's Duravyu uses a sustained-release formulation that can reduce injection frequency, making the therapy highly attractive to physicians and patients if approved.
Because of Duravyu's tremendous potential, Wall Street is overwhelmingly bullish about EyePoint. All 12 analysts surveyed by S&P Global (SPGI +3.78%) in June rated the stock as a "buy" or "strong buy." The consensus 12-month price target is 165% higher than EyePoint's current share price.
To be sure, FDA approval of Duravyu isn't a slam dunk. Neither is commercial success. However, EyePoint's prospects of doubling over the next couple of years appear much higher than SpaceX's.
3. Viking Therapeutics When most people think about investing in GLP-1 stocks, Eli Lilly (LLY +7.51%) and Novo Nordisk (NVO +1.00%) probably come to mind first. But another stock appears to be on track to give Lilly and Novo a run for their money: Viking Therapeutics (VKTX +2.79%).
Viking Therapeutics is in the same boat as EyePoint Pharmaceuticals in some respects. The company remains unprofitable because it doesn't yet have an approved drug. However, like EyePoint, Viking could have good news on the way. It's evaluating the lead obesity candidate, subcutaneous VK2735, in two Phase 3 trials. The drugmaker plans to begin another late-stage study of oral VK2735 in the fourth quarter of 2026. Both formulations of VK2735 have shown significant promise in earlier clinical trials.
Today's Change
(
2.79
%) $
1.03
Current Price
$
38.02
In addition, Viking's pipeline includes three other experimental therapies in clinical development. VK2809 completed a Phase 2 study targeting metabolic steatohepatitis (MASH), a fatty liver disease. VK-0214 is in early stage testing as a potential treatment for X-linked adrenoleukodystrophy, a rare genetic disease. Viking also recently initiated a Phase 1 study of VK3019 as a weight-loss treatment.
Investing in Viking Therapeutics comes with risks. However, the upside is enormous. As a case in point, the average price target for the stock is 146% higher than Viking's current share price.
June has been a history-maker for Wall Street. Not only did the Dow Jones Industrial Average, S&P 500, and Nasdaq Composite catapult to new highs earlier this month, but investors also witnessed the largest-ever initial public offering (IPO) take shape, courtesy of Space Exploration Technologies (SpaceX)(SPCX +0.15%).
Elon Musk's artificial intelligence (AI) and space economy conglomerate debuted on June 12 and ultimately raised $85.7 billion (including the underwriters' overallotment) -- nearly triple the amount that overseas oil giant Saudi Aramco raised with its December 2019 IPO.
Image source: Getty Images.
However, the biggest fireworks for SpaceX are yet to come. Thanks to two converging events, July 7 is shaping up to be a monster day for this $2 trillion AI and space company.
Nasdaq-100 inclusion is right around the corner Before SpaceX went public, several committees amended the criteria for the inclusion of megacap stocks in major indexes.
For instance, the U.S. Russell Indexes drastically shortened the inclusion timeline for newly public large-cap stocks from once per quarter to just five trading sessions.
But the headline change came courtesy of the Nasdaq (NDAQ +1.24%) Global Indexes. Effective May 1, the low float requirement for inclusion in the Nasdaq-100 has been waived.
To be clear, this means only the S&P 500 will exclude SpaceX shortly after its IPO.
FTSE Russell adds eligible megacap IPOs after the close of the 5th trading day.
Nasdaq adds them about 15 trading days after listing.
The S&P 500 kept its rules, so SpaceX waits the full...
-- Hedgeye (@Hedgeye) June 4, 2026 More importantly, any non-financial company that would rank among the 40 largest companies in the Nasdaq-100 can be fast-tracked into the index after 15 trading days. Accounting for the Juneteenth and Independence Day holidays, July 6 marks the 15th trading day for SpaceX stock.
As early as July 7, SpaceX will be eligible for addition to the growth-stock-dominated Nasdaq-100. Index funds and growth-focused exchange-traded funds that track the Nasdaq-100 will be required to purchase shares of SpaceX stock. The company's inclusion in the Russell 1000, Russell 3000, and Nasdaq-100 should lead to tens of billions of dollars in buying demand.
Image source: Getty Images.
The participating underwriters' quiet period ends However, Nasdaq-100 inclusion eligibility isn't the only catalyst that aligns on July 7. It's also the end of the participating underwriters' quiet period.
Most IPOs have a lead underwriter and a couple of participating underwriters (usually major banks/financial institutions). SpaceX had 21 underwriters, with Goldman Sachs as the lead.
For participating (i.e., non-lead) underwriters, Securities and Exchange Commission (SEC) rules mandate a 25-calendar-day quiet period following an IPO. During this period, participating underwriters are forbidden from issuing research reports or initiating recommendations/price targets for the company they helped take public.
The SEC requires this quiet period to ensure that underwriters don't unfairly promote a company in which they may have a vested interest.
July 6 will mark the 25th calendar day since SpaceX went public (including its debut day). This means a likely onslaught of buy recommendations and lofty price targets set to be issued on SpaceX starting on July 7.
Great look at the SpaceX shares unlock schedule as well as the potential passive buying schedule from @JSeyff @FrancisSharoon Depending on the early post-IPO returns, this could really play with and disperse the returns of "passive" funds (which is why there's arguably no such... pic.twitter.com/KOuEkJlngF
-- Eric Balchunas (@EricBalchunas) May 28, 2026 While this perfect storm of positive catalysts could provide a sizable boost to SpaceX's shares next week, keep in mind that Musk's company also has an accelerated/staggered share lockup period. Insiders will have an opportunity to begin dumping their shares on retail investors as soon as the second trading day following the company's first quarterly earnings release as a public company in August.
In other words, whatever pop SpaceX enjoys on and shortly after July 7 is likely to dissipate in the weeks that follow.
The shares should be getting a boost Monday as it's set to begin trading in a major stock index for the first time, after joining the Russell 1000 after the close Friday.
Apple (AAPL +3.37%) shocked Wall Street last week when it raised prices across most of its hardware lineup. Macs, iPads, the Apple TV, the HomePod, and the Vision Pro headset all got more expensive -- increases of about $100 to $300 (with a few high-end Macs getting even bigger increases) -- and the company tied the move to a shortage of memory chips brought on by the build-out of artificial intelligence (AI) data centers.
"The rapid expansion of AI data centers has created an extraordinary surge in demand for memory and storage," Apple said.
Investors didn't take it well, and the stock had its worst day in more than a year.
Its most important product, however, was conspicuously missing from the list: the iPhone. Of course, so were the Apple Watch and AirPods. But the iPhone's absence from the list of products with price hikes is particularly notable. After all, the device still drives about half of Apple's revenue.
This leaves a big question for investors and consumers: Is the iPhone next? And if so, when are the increases coming?
Image source: Apple.
Why the iPhone got a pass There actually is one simple explanation as to why iPhone price increases may have been left out in this round: timing. Apple is expected to introduce new iPhone models this September, and this is a natural moment to reset pricing. Raising the price on phones already sitting on shelves, in the middle of a cycle, would be far more conspicuous than folding a higher number into a new lineup that buyers are weighing on its features anyway.
Additionally, the iPhone is also the entry point to nearly everything else Apple sells -- the services, the accessories, the next device -- so it may be the last product the company wants to disturb.
And it can afford to wait. Apple is taking on these costs from a position of unusual strength. In its fiscal second quarter (the period ended March 28, 2026), revenue rose 17% year over year to $111.2 billion, and earnings per share climbed 22% to $2.01. iPhone revenue set a March-quarter record, rising about 22%, and services reached an all-time high. Gross margin came in at a record 49.3%. A business running margins like that has room to absorb higher component costs for a while before it has to pass them along.
But the memory crisis may be getting harder to ignore. Conventional memory contract prices have soared this year -- up about 90% to 95% quarter over quarter in Q1 as supply shifts toward the high-bandwidth memory used in AI servers. And memory contract prices are expected to rise sharply in Q2, too.
How Apple could raise iPhone prices Ultimately, I think an iPhone price increase this fall looks likely. The harder question, however, is how big the price increase will be and what it will do to demand.
Given that price increases for most of its products so far have largely ranged from $100 to $300, I think it's reasonable to assume that iPhone price hikes would come in at around $100 or higher.
But how would Apple go about raising prices on the iPhone? It's complicated because Apple has a number of levers. For example, it can raise the entry storage tier or lift the Pro phones while keeping the base model steady, rather than raising the price on every model.
Estimating how it may impact demand may be even harder. Apple boasts impressive customer loyalty. But could higher prices push customers to delay iPhone upgrades longer than they otherwise would?
On the positive side, a higher price protects Apple's gross margin, but only if it doesn't suppress upgraders too much. Push too hard, and a price increase meant to defend margins can end up shrinking unit sales too much, offsetting gains from margin protection.
Today's Change
(
3.37
%) $
9.28
Current Price
$
284.43
So, what would iPhone price increases look like? My best guess is they occur this fall, and in a measured way -- largely concentrated on the Pro models, or tucked into versions with higher storage tiers rather than a blunt increase across the board.
With all of this said, raising prices on the iPhone isn't a given. With the stock trading at a price-to-earnings ratio of about 34, the valuation already leans on continued growth, giving the company every reason to defend its record margins. But it has just as much reason to protect the upgrade cycle that makes the iPhone its most valuable product. The new lineup is still a few months out, which leaves Apple time to decide how much of the memory squeeze its customers will end up paying for.
Last year, Warren Buffett corrected one of his previous investing mistakes. He initiated a sizable position in Google parent Alphabet (GOOG 2.15%) (GOOGL 1.73%), several years after admitting that he regretted not buying the stock earlier.
After Buffett stepped down as Berkshire Hathaway's (BRKA +1.60%) (BRKB +2.08%) CEO at the end of 2025, his successor, Greg Abel, more than tripled the conglomerate's stake in Alphabet. The stock now ranks as Berkshire's fifth-largest holding.
But Google's stock has fallen by double digits over the past few weeks. Are Buffett and Abel worried that they made a mistake buying the stock? I don't think so. If you own shares of Alphabet, here's why you shouldn't be worried, either.
Image source: Getty Images.
Why the stock's decline isn't really scary Three factors explain Alphabet's decline since May. None of them should be scary to investors, in my opinion.
First, Alphabet's first-quarter update revealed another significant increase in planned capital expenditures. The company provided capex guidance of $180 billion to $190 billion for full-year 2026. Some investors have become jittery over the sky-high spending on artificial intelligence (AI) infrastructure by Alphabet and other tech giants.
Second (and related to the first factor), Alphabet announced in June that it was raising $80 billion through private placement equity offerings. The company said that these offerings are part of the plan "to fund investments in its world-class AI compute infrastructure to meet its unprecedented customer demand."
Third, two high-profile defections last week caused the stock to experience its worst day in more than a year. Noam Shazeer, Google's vice president of engineering and one of the leaders of the Gemini AI models, announced he was leaving to join OpenAI. Two days later, Google DeepMind vice president and engineering fellow John Jumper announced that he was leaving to join Anthropic. Jumper received a Nobel Prize with Google DeepMind CEO Demis Hassabis for developing AlphaFold, an AI system that predicts protein structures.
Anat Askkenazi, CFO of Alphabet and Google, said in the Q1 update that the company continues to see "unprecedented internal and external demand for AI compute resources." Ashkenazi pointed out that investments in AI infrastructure are driving record revenue and backlog growth.
What about the departures of key AI leaders? It is somewhat concerning. However, this kind of musical chairs is commonplace in the industry. Alphabet still has a huge level of AI talent and the money to recruit more people.
Today's Change
(
-1.73
%) $
-5.95
Current Price
$
337.76
I have no doubt whatsoever that neither Buffett nor Abel is losing sleep over the factors behind Alphabet's recent sell-off. For one thing, Abel led the charge for Berkshire's additional $10 billion investment in Alphabet that was part of the private placement. If he had any qualms about Alphabet spending more on AI infrastructure, he would never have committed such a significant amount of Berkshire's capital.
It's important to remember Buffett's perspective on stock declines. At Berkshire Hathaway's 2010 annual shareholder meeting, he said, "If you have a temperament that when others are fearful you're going to get scared yourself, you know, you are not going to make a lot of money in securities over time, in all probability."
What's more, the legendary investor gave a decidedly contrarian opinion. He stated that some investors buy a stock and then "think if it goes up it's wonderful, and if it goes down it's bad." Buffett explained, "We think just the opposite. When it goes down, we love it, because we'll buy more. And if it goes up, it kills us to buy more."
An opportunity for long-term investors As usual, Buffett was right. A pullback in a wonderful company's share price presents an excellent buying opportunity for long-term investors. And Alphabet remains a wonderful company.
The record Google Cloud backlog provides excellent revenue visibility. Google Search continues to grow, with generative AI serving as a tailwind rather than the "Google killer" some predicted. Waymo is the leader in autonomous ride-hailing. Alphabet is even now part of the Dow Jones Industrial Average (^DJI 0.09%), reflecting how important it has become to the U.S. economy.
Don't be surprised if Berkshire's next 13-F filing reveals that the conglomerate took advantage of Alphabet's decline to load up on more shares. After all, that's the Warren Buffett way.
Microsoft (MSFT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Nvidia CEO Jensen Huang. Bloomberg/Getty Images Nvidia's AI ambitions are officially out of this world this year, and they haven't come back down to Earth.
The AI chip giant is adding to the team behind Space-1, its first computing system designed for space. In recent weeks, the chip giant posted a second job tied to orbital data centers.
The role — for a system software principal architect — will help build software for Space-1, which the chip giant unveiled at its GTC event in March.
Space data centers have emerged as a potential way to get around growing constraints on land, power, and cooling on Earth. Companies like SpaceX are racing to make the idea a reality, while skeptics argue the costs still outweigh the benefits.
During a recent earnings call, Nvidia CEO Jensen Huang said the economics around space computing are poor today but will improve over time.
The principal architect job post follows another role shared earlier this year for an orbital data center system architect. While that position focuses on designing the overall system — from computing hardware to satellites to connectivity systems — the new post focuses on making Space-1's software work in practice.
The person hired will design the software that runs the system so it can withstand radiation and extreme temperature swings and be managed remotely.
Space-1 harnesses Nvidia's latest Vera Rubin AI chip platform and is designed for low-Earth orbit missions.
The system software role requires previous experience building AI infrastructure and systems in space. It offers a base salary of $272,000 to $431,250, which doesn't include Nvidia's coveted equity awards.
While the technology is still in its early stages, Nvidia's latest job postings suggest the chipmaker is moving from conceptual planning to building the systems needed to make it work.
Have a tip? Contact this reporter via email at [email protected] or Signal at @geoffweiss.25. Use a personal email address, a nonwork WiFi network, and a nonwork device; here's our guide to sharing information securely.
Read next
Geoff Weiss You're currently following this author! Want to unfollow? Unsubscribe via the link in your email.
Geoff Weiss is a senior reporter on Business Insider’s tech team, where he writes about AI startups and Y Combinator, the intersection of AI and the media industry, and workplace dynamics within top AI labs and chip companies.Previously, Geoff was on the media desk, covering YouTube and Netflix, and themes like the intersection of Hollywood and the creator economy. His work on Netflix’s video podcasting ambitions and Mr Beast’s lessons for Hollywood won second and first prize, respectively, at the 2025 LA Press Club Awards.Prior to joining Business Insider, Geoff was the senior editor of Tubefilter and a staff writer at Entrepreneur. He graduated from New York University with a degree in English Literature.He can be reached at [email protected], on Signal @geoffweiss.25, and on LinkedIn. Have a tip? Use a personal email address and a nonwork device; here's our guide to sharing information securely.Selected stories:Nvidia crushed its quarter — and CEO Jensen Huang said in a leaked all-hands that 'the market did not appreciate it'Nvidia will foot the bill for Trump's new visa fees. Here's what CEO Jensen Huang told staff.Massive AI salaries and RTO are fueling a real estate boom in San Francisco: 'It's going to rain money'The AI talent wars are ricocheting across startups. Here's how they're competing with Big Tech.
For more than 130 years, the Dow Jones Industrial Average (^DJI 0.09%) has served as one of Wall Street's most trusted barometers. What was once a 12-stock index dominated by industrial companies in the late 1890s is now comprised of 30 multinational businesses from a variety of sectors.
Change is part of the Dow's storied history -- and today, June 29, features the 54th time since its inception that companies will be added or removed. Telecom titan Verizon Communications (VZ +0.83%) is being shown the door, Google parent Alphabet (GOOGL 1.73%)(GOOG 2.19%) is being added, and the Dow's biggest laggard, Nike (NKE 0.31%), is officially on notice.
Image source: Getty Images.
Alphabet officially replaces Verizon in the Dow Although Verizon is a staple in high-yield income portfolios, and it continues to deliver predictable wireless and broadband operating results, its 22-year run in the Dow came to an end for two reasons.
The first issue for Verizon is its comparatively low share price. Unlike most major stock indexes, the Dow Jones Industrial Average is share-price weighted. The higher a company's share price, the more influence it has within the index. Verizon's $45.68 share price (as of June 24) accounts for just 0.5% of the Dow's weighting.
The other death knell for Verizon is that it didn't perform. Since its addition in April 2004, Verizon's shares gained a paltry 36%, excluding dividends.
Alphabet's Class A shares (GOOGL) resolve both of Verizon's shortcomings. Alphabet's shares have rallied nearly 13,700% since debuting in August 2004, and its $345.29 share price will make it the sixth most influential company in the Dow.
Today's Change
(
-1.73
%) $
-5.95
Current Price
$
337.76
Alphabet's addition also makes the Dow Jones Industrial Average more representative of the U.S. economy. Google is practically a monopoly in internet search, accounting for a shade over 90% of global search engine traffic in May 2026. When coupled with Alphabet's ownership of YouTube, the second-most-visited social site on the planet, you get a dominant ad-driven business.
But Alphabet is more than just ads. The company's cloud infrastructure services platform, Google Cloud, has seen sales reaccelerate after integrating generative AI and large language model solutions. The world's No. 3 cloud infrastructure services platform delivered 63% sales growth in the first quarter.
Alphabet is an artificial intelligence applications pioneer, making it an ideal addition to the iconic Dow.
Image source: Getty Images.
Nike has been put on notice While S&P Dow Jones Indices, the committee responsible for adjusting the Dow Jones Industrial Average, only announced one addition (Alphabet, GOOGL) and one subtraction (Verizon), the message is clear: footwear and apparel giant Nike's 13-year tenure in the Dow may soon end.
No Dow component has less influence than Nike, whose share price fell below $42 on June 24. Additionally, Nike's five-year swoon has practically given back all of its gains since its September 2013 addition to the Dow.
Today's Change
(
-0.31
%) $
-0.13
Current Price
$
40.77
At the heart of this decline is Nike's direct-to-consumer push, which ultimately hurt its relationship with wholesalers. The company's international sales (specifically in China) have also taken a beating as competition has intensified.
If Nike doesn't right the ship quickly, it'll likely be following Verizon out the door.
, /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against First Solar, Inc. ("First Solar" or "the Company") (NASDAQ: FSLR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Shareholders who purchased shares of FSLR during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments. Appointment as lead plaintiff is not required to partake in any recovery.
CLASS PERIOD: February 26, 2025 to February 24, 2026
DEADLINE: August 24, 2026
CASE DETAILS: According to the Complaint, the Company made false and misleading statements to the market. First Solar overstated its ability to shift operations from Asia to the United States. The Company misled the market with its supposed plans to manage the impact of U.S. tariffs. Based on these facts, First Solar's public statements were false and materially misleading throughout the class period.
If you are a shareholder who suffered a loss, contact us to participate.
WHY DJS LAW GROUP? DJS Law Group's primary focus is to enhance investor return through balanced counseling and aggressive advocacy. We specialize in securities class actions, corporate governance litigation, and domestic/international M&A appraisals. Our clients are some of the largest and most sophisticated hedge funds and alternative asset managers in the world. The litigation claims of our clients are extraordinarily valuable assets that demand respect, focus, and results.
Join the case to recover your losses.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
CONTACT:
David J. Schwartz
DJS Law Group
274 White Plains Road, Suite 1
Eastchester, NY 10709
Phone: 914-206-9742
Email: [email protected]
, /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against First Solar, Inc. ("First Solar" or "the Company") (NASDAQ: FSLR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Investors who purchased the Company's securities between February 26, 2025 and February 24, 2026, inclusive (the "Class Period"), are encouraged to contact the firm before August 24, 2026.
If you are a shareholder who suffered a loss, click here to participate.
We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at [email protected].
The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.
According to the Complaint, the Company made false and misleading statements to the market. First Solar misled investors about its ability to mitigate the impact of tariffs on its operations. The Company overstated its ability to shift operations to the United States from Malaysia and Vietnam. Based on these facts, the Company's public statements were false and materially misleading throughout the class period. When the market learned the truth about First Solar, investors suffered damages.
Join the case to recover your losses
The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
CONTACT:
The Schall Law Firm
Brian Schall, Esq.,
www.schallfirm.com
Office: 310-301-3335
[email protected]
Positive CHMP opinion is supported by data from the Phase 3 UP-AA clinical program in which upadacitinib achieved the primary endpoint of Severity of Alopecia Tool (SALT) score ≤ 20 and key secondary endpoints, including improvements in eyebrows and eyelashes, at week 241,2 Upadacitinib is the first JAK inhibitor to meet the stringent ranked secondary endpoint of complete scalp hair regrowth (SALT = 0) at week 241,2 , /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the approval of upadacitinib (RINVOQ®; 15 mg and 30 mg, once daily) for the treatment of adult and adolescent patients with severe alopecia areata (AA). The final European Commission decision is expected in the coming months.
"Alopecia areata is an unpredictable autoimmune disease with underrecognized patient burden," said Roopal Thakkar, M.D., executive vice president, research and development, chief scientific officer, AbbVie. "The CHMP's positive opinion for upadacitinib is a step closer to bringing a new treatment option to patients living with severe alopecia areata."
The CHMP positive opinion is supported by data from the ongoing Phase 3 UP-AA clinical program (M23-716), which includes two replicate, randomized, placebo-controlled, double-blind studies evaluating the efficacy and safety of upadacitinib in adult and adolescent patients with severe alopecia areata. Both the 15 mg and 30 mg doses of upadacitinib in each study met the primary endpoint of SALT score ≤ 20 at week 24, with significantly more patients achieving ≥ 80% scalp hair coverage compared with placebo. Key secondary endpoints were also met for both doses in both studies, including complete scalp hair regrowth (SALT = 0) at week 24. The safety profile of both doses of upadacitinib in Period A was generally consistent with that observed in approved indications.1,2
Upadacitinib is approved in the European Union (EU) for the treatment of adults and adolescents with atopic dermatitis, and adults with radiographic axial spondylarthritis, non-radiographic axial spondylarthritis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, Crohn's disease, and giant cell arteritis. Use of upadacitinib in AA is not currently approved in the EU.
About Alopecia Areata
Alopecia areata (AA) is an unpredictable autoimmune disease causing a range of hair loss patterns, from sudden, round bald patches on the scalp to complete loss of all body hair, including scalp, face, eyebrows and eyelashes.3,4 Despite its immune-mediated nature, AA is often considered a cosmetic problem, which can lead to stigma and have an impact on patients' lives.5,6
About UP-AA Clinical Trial
UP-AA M23-716 was conducted as a single protocol that includes two replicate pivotal studies (Study 1 and Study 2) with randomization, investigative sites, data collection, analysis and reporting independent for each study. The Phase 3 randomized, placebo-controlled, double-blind studies evaluate efficacy and safety of upadacitinib in adult and adolescent subjects with severe alopecia areata. In Study 1 and Study 2 Period A, participants are randomized to one of three groups to receive upadacitinib 15 mg, upadacitinib 30 mg or placebo for 24 weeks. In Study 1 and Study 2 Period B, participants originally randomized to upadacitinib dose groups in Period A will continue their same treatment in Period B for 28 weeks. Participants originally randomized to placebo in Period A will either remain on placebo in Period B, or be randomized in one of two groups, based on their SALT score at week 24. In total, Study 1 and Study 2 Periods A and B span 52 weeks. Participants who complete Study 1 or Study 2 can join Study 3 and may be re-randomized to receive 1 of 2 doses of upadacitinib for up to 108 weeks. The two trials randomized 1,399 participants with severe AA ages 12 to 64 across 248 sites worldwide. More information on this trial can be found at www.clinicaltrials.gov (NCT06012240).
About RINVOQ® (upadacitinib)
Discovered and developed by AbbVie scientists, RINVOQ is a JAK inhibitor that is being studied in several immune-mediated inflammatory diseases. Based on enzymatic and cellular assays, RINVOQ demonstrated greater inhibitory potency for JAK-1 vs JAK-2, JAK-3, and TYK-2. The relevance of inhibition of specific JAK enzymes to therapeutic effectiveness and safety is not currently known.
Upadacitinib (RINVOQ) is being studied in Phase 3 clinical trials for alopecia areata, hidradenitis suppurativa, Takayasu arteritis, systemic lupus erythematosus, and vitiligo. The use of upadacitinib in alopecia areata is not approved; its safety and efficacy are under regulatory review by the U.S. FDA and the European Medicines Agency.
EU Indications and Important Safety Information about RINVOQ® (upadacitinib)7
Indications
Rheumatoid arthritis
RINVOQ is indicated for the treatment of moderate to severe active rheumatoid arthritis (RA) in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (DMARDs). RINVOQ may be used as monotherapy or in combination with methotrexate.
Psoriatic arthritis
RINVOQ is indicated for the treatment of active psoriatic arthritis (PsA) in adult patients who have responded inadequately to, or who are intolerant to one or more DMARDs. RINVOQ may be used as monotherapy or in combination with methotrexate.
RINVOQ is indicated for the treatment of active non-radiographic axial spondyloarthritis in adult patients with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI), who have responded inadequately to nonsteroidal anti-inflammatory drugs (NSAIDs).
RINVOQ is indicated for the treatment of active ankylosing spondylitis in adult patients who have responded inadequately to conventional therapy.
Giant cell arteritis
RINVOQ is indicated for the treatment of giant cell arteritis (GCA) in adult patients.
Atopic dermatitis
RINVOQ is indicated for the treatment of moderate to severe atopic dermatitis (AD) in adults and adolescents 12 years and older who are candidates for systemic therapy.
Ulcerative colitis
RINVOQ is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.
Crohn's disease
RINVOQ is indicated for the treatment of adult patients with moderately to severely active Crohn's disease who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.
Important Safety Information
Contraindications
RINVOQ is contraindicated in patients hypersensitive to the active substance or to any of the excipients, in patients with active tuberculosis (TB) or active serious infections, in patients with severe hepatic impairment, and during pregnancy.
Special warnings and precautions for use
RINVOQ should only be used if no suitable treatment alternatives are available in patients:
65 years of age and older; patients with history of atherosclerotic cardiovascular (CV) disease or other CV risk factors (such as current or past long-time smokers); patients with malignancy risk factors (e.g. current malignancy or history of malignancy) Use in patients 65 years of age and older
Considering the increased risk of MACE, malignancies, serious infections, and all-cause mortality in patients ≥65 years of age, as observed in a large randomised study of tofacitinib (another Janus Kinase (JAK) inhibitor), RINVOQ should only be used in these patients if no suitable treatment alternatives are available. In patients ≥65 years of age, there is an increased risk of adverse reactions with RINVOQ 30 mg once daily. Consequently, the recommended dose for long-term use in this patient population is 15 mg once daily.
Immunosuppressive medicinal products
Use in combination with other potent immunosuppressants is not recommended.
Serious infections
Serious and sometimes fatal infections have been reported in patients receiving RINVOQ. The most frequent serious infections reported included pneumonia and cellulitis. Cases of bacterial meningitis and sepsis have been reported with RINVOQ. Among opportunistic infections, TB, multidermatomal herpes zoster, oral/esophageal candidiasis, and cryptococcosis have been reported. RINVOQ should not be initiated in patients with an active, serious infection, including localized infections. RINVOQ should be interrupted if a patient develops a serious or opportunistic infection until the infection is controlled. A higher rate of serious infections was observed with RINVOQ 30 mg compared to 15 mg. As there is a higher incidence of infections in the elderly and patients with diabetes in general, caution should be used when treating these populations. In patients ≥65 years of age, RINVOQ should only be used if no suitable treatment alternatives are available.
Tuberculosis
Patients should be screened for TB before starting RINVOQ. RINVOQ should not be given to patients with active TB. Anti-TB therapy may be appropriate for select patients in consultation with a physician with expertise in the treatment of TB. Patients should be monitored for the development of signs and symptoms of TB.
Viral reactivation
Viral reactivation, including cases of herpes zoster, was reported in clinical studies. The risk of herpes zoster appears to be higher in Japanese patients treated with RINVOQ. Consider interruption of RINVOQ if the patient develops herpes zoster until the episode resolves. Screening for viral hepatitis and monitoring for reactivation should occur before and during therapy. If hepatitis B virus DNA is detected, a liver specialist should be consulted.
Vaccination
The use of live, attenuated vaccines during or immediately prior to therapy is not recommended. It is recommended that patients be brought up to date with all immunizations, including prophylactic zoster vaccinations, prior to initiating RINVOQ, in agreement with current immunization guidelines.
Malignancy
Lymphoma and other malignancies have been reported in patients receiving JAK inhibitors, including RINVOQ. In a large randomised active‑controlled study of tofacitinib (another JAK inhibitor) in RA patients ≥50 years of age with ≥1 additional CV risk factor, a higher rate of malignancies, particularly lung cancer, lymphoma, and non-melanoma skin cancer (NMSC), was observed with tofacitinib compared to tumour necrosis factor (TNF) inhibitors. A higher rate of malignancies, including NMSC, was observed with RINVOQ 30 mg compared to 15 mg. Periodic skin examination is recommended for all patients, particularly those with risk factors for skin cancer. In patients ≥65 years of age, patients who are current or past long-time smokers, or patients with other malignancy risk factors (e.g., current malignancy or history of malignancy), RINVOQ should only be used if no suitable treatment alternatives are available.
Hematological abnormalities
Treatment should not be initiated, or should be temporarily interrupted, in patients with hematological abnormalities observed during routine patient management.
Gastrointestinal perforations
Events of diverticulitis and gastrointestinal perforations have been reported in clinical trials and from post-marketing sources. RINVOQ should be used with caution in patients who may be at risk for gastrointestinal perforation (e.g., patients with diverticular disease, a history of diverticulitis, or who are taking non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids, or opioids. Patients with active Crohn's disease are at increased risk for developing intestinal perforation. Patients presenting with new onset abdominal signs and symptoms should be evaluated promptly for early identification of diverticulitis or gastrointestinal perforation.
Major adverse cardiovascular events
MACE were observed in clinical studies of RINVOQ. In a large randomised active-controlled study of tofacitinib (another JAK inhibitor) in RA patients ≥50 years of age with ≥1 additional CV risk factor, a higher rate of MACE, defined as CV death, non-fatal myocardial infarction and non-fatal stroke, was observed with tofacitinib compared to TNF inhibitors. Therefore, in patients ≥65 years of age, patients who are current or past long-time smokers, and patients with history of atherosclerotic CV disease or other CV risk factors, RINVOQ should only be used if no suitable treatment alternatives are available.
Lipids
RINVOQ treatment was associated with dose-dependent increases in lipid parameters, including total cholesterol, low-density lipoprotein cholesterol, and high-density lipoprotein cholesterol.
Hepatic transaminase elevations
Treatment with RINVOQ was associated with an increased incidence of liver enzyme elevation. Hepatic transaminases must be evaluated at baseline and thereafter according to routine patient management. If alanine transaminase (ALT) or aspartate transaminase (AST) increases are observed and drug-induced liver injury is suspected, RINVOQ should be interrupted until this diagnosis is excluded.
Venous thromboembolism
Events of deep venous thrombosis (DVT) and pulmonary embolism (PE) were observed in clinical trials for RINVOQ. In a large randomised active-controlled study of tofacitinib (another JAK inhibitor) in RA patients ≥50 years of age with ≥1 additional CV risk factor, a dose‑dependent higher rate of VTE including DVT and PE was observed with tofacitinib compared to TNF inhibitors. In patients with CV or malignancy risk factors, RINVOQ should only be used if no suitable treatment alternatives are available. In patients with known VTE risk factors other than CV or malignancy risk factors (e.g. previous VTE, patients undergoing major surgery, immobilisation, use of combined hormonal contraceptives or hormone replacement therapy, and inherited coagulation disorder), RINVOQ should be used with caution. Patients should be re-evaluated periodically to assess for changes in VTE risk. Promptly evaluate patients with signs and symptoms of VTE and discontinue RINVOQ in patients with suspected VTE.
Retinal vein occlusion
Retinal vein occlusion has been reported in patients treated with JAK inhibitors, including upadacitinib. Patients should be advised to promptly seek medical care in case they experience symptoms suggestive of retinal vein occlusion.
Hypersensitivity reactions
Serious hypersensitivity reactions such as anaphylaxis and angioedema have been reported in patients receiving RINVOQ. If a clinically significant hypersensitivity reaction occurs, discontinue RINVOQ and institute appropriate therapy.
Hypoglycemia in patients treated for diabetes
There have been reports of hypoglycemia following initiation of JAK inhibitors, including RINVOQ, in patients receiving medication for diabetes. Dose adjustment of anti-diabetic medication may be necessary in the event that hypoglycemia occurs.
Medication Residue in Stool
Reports of medication residue in stool or ostomy output have occurred in patients taking RINVOQ. Most reports described anatomic (e.g., ileostomy, colostomy, intestinal resection) or functional gastrointestinal conditions with shortened gastrointestinal transit times. Patients should be instructed to contact their healthcare professional if medication residue is observed repeatedly. Patients should be clinically monitored, and alternative treatment should be considered if there is an inadequate therapeutic response.
Giant Cell Arteritis
RINVOQ monotherapy should not be used for the treatment of acute relapses as efficacy in this setting has not been established. Corticosteroids should be given according to medical judgement and practice guidelines.
Adverse reactions
The most commonly reported adverse reactions in RA, PsA, and axSpA clinical trials (≥2% of patients in at least one of the indications) with RINVOQ 15 mg were upper respiratory tract infections, blood creatine phosphokinase (CPK) increased, ALT increased, bronchitis, nausea, neutropenia, cough, AST increased, and hypercholesterolemia. Overall, the safety profile observed in patients with psoriatic arthritis or active axial spondyloarthritis treated with RINVOQ 15 mg was consistent with the safety profile observed in patients with RA.
The most commonly reported adverse reactions in AD trials (≥2% of patients) with RINVOQ 15 mg or 30 mg were upper respiratory tract infection, acne, herpes simplex, headache, blood CPK increased, cough, folliculitis, abdominal pain, nausea, neutropenia, pyrexia, and influenza. Dose dependent increased risks of infection and herpes zoster were observed with RINVOQ. The safety profile for RINVOQ 15 mg and 30 mg in adolescents was similar to that in adults. With long-term exposure, skin papilloma was reported in adolescents in the RINVOQ 15 mg and 30 mg groups.
The most commonly reported adverse reactions in the UC and CD trials (≥3% of patients) with RINVOQ 45 mg, 30 mg or 15 mg were upper respiratory tract infection, pyrexia, blood CPK increased, anemia, headache, acne, herpes zoster, neutropenia, rash, pneumonia, hypercholesterolemia, bronchitis, AST increased, fatigue, folliculitis, ALT increased, herpes simplex, and influenza. The overall safety profile observed in patients with UC was generally consistent with that observed in patients with RA. Overall, the safety profile observed in patients with CD treated with RINVOQ was consistent with the known safety profile for RINVOQ.
Overall, the safety profile observed in patients with GCA treated with RINVOQ 15 mg was generally consistent with the known safety profile for RINVOQ.
The most common serious adverse reactions were serious infections.
The safety profile of RINVOQ with long-term treatment was generally similar to the safety profile during the placebo-controlled period across indications.
This is not a complete summary of all safety information.
See RINVOQ full Summary of Product Characteristics (SmPC) at www.ema.europa.eu.
Globally, prescribing information varies; refer to the individual country product label for complete information.
About AbbVie in Immunology
AbbVie is relentless in our pursuit to redefine the standard of care for patients living with immune-mediated conditions, with the goal of helping them live a life free from the limitations of their disease. For more than 20 years, AbbVie has led and helped shape the field of immunology through groundbreaking science and trusted medicines. Building on deep expertise across gastroenterology, rheumatology and dermatology, and other areas of high unmet need, we continue to invest in a broad and differentiated pipeline – spanning innovative modalities, novel mechanisms of actions and next-generation approaches designed to conquer the complex biology underlying immune-mediated disease.
Today, more than 1 million patients worldwide are treated with AbbVie's immunology medicines, approved in more than 175 countries across 19 immune-mediated diseases that impact adult and pediatric populations. As we work to strengthen our legacy and drive the next wave of innovation, we remain focused on delivering meaningful progress for patients and expanding access to our medicines. For more information, please visit www.abbvie.com/immunology.
About AbbVie
AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas including immunology, neuroscience and oncology – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on LinkedIn, Facebook, Instagram, X and YouTube.
Forward-Looking Statements
Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words "believe," "expect," "anticipate," "project" and similar expressions and uses of future or conditional verbs, generally identify forward-looking statements. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. Such risks and uncertainties include, but are not limited to, challenges to intellectual property, competition from other products, difficulties inherent in the research and development process, adverse litigation or government action, changes to laws and regulations applicable to our industry, the impact of global macroeconomic factors, such as economic downturns or uncertainty, international conflict, trade disputes and tariffs, and other uncertainties and risks associated with global business operations. Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie's operations is set forth in Item 1A, "Risk Factors," of AbbVie's 2025 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission, as updated by its Quarterly Reports on Form 10-Q and in other documents that AbbVie subsequently files with the Securities and Exchange Commission that update, supplement or supersede such information. AbbVie undertakes no obligation, and specifically declines, to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.
References
AbbVie. Data on file ABVRRTI81580. AbbVie. Data on file ABVRRTI81456. Alkhalifah A, Alsantali A, Wang E, McElwee KJ, Shapiro J. Alopecia areata update: Part I. Clinical picture, histopathology, and pathogenesis. J Am Acad Dermatol. 2010;62(2):177-188, quiz 189-190. Pratt CH, King LE, Messenger AG, Christiano AM, Sundberg JP. Alopecia areata. Nat Rev Dis Primers. 2017;3(1):17011 Davey L, Clarke V, Jenkinson E. Living with alopecia areata: an online qualitative survey study. Br J Dermatol. 2019;180(6):1377-1389 Bain KA, McDonald E, Moffat F, et al. Alopecia areata is characterized by dysregulation in systemic type 17 and type 2 cytokines, which may contribute to disease-associated psychological morbidity. Br J Dermatol. 2020;182(1):130-137 RINVOQ [Package Insert]. North Chicago, IL: AbbVie Inc.; 2026 SOURCE AbbVie
Crucial Support Under SiegeThe recent slide has pushed QQQ below its 20-day simple moving average (SMA) of $724.72, threatening a larger trend reversal, according to Benzinga Pro. Bearish momentum is accelerating as the MACD indicator undergoes a negative crossover, while the RSI has plunged to 46.45.
Traders are now eyeing the immediate floor at the 50-day SMA of $702.78. A definitive close below this crucial support could trigger systematic liquidation toward the 100-day SMA at $651.76.
Unprecedented Volatility DisconnectWhile tech indexes slip, options markets are flashing signals unseen since the dot-com era. According to The Kobeissi Letter, the spread between the tech-heavy volatility index ($VXN) and the broader market counterpart ($VIX) has blown out to 12 points—the highest in at least 23 years.
Fundamental BackstopDespite the steep technical correction and record-high fear gauges, underlying corporate fundamentals remain exceptionally strong. Data from Goldman Sachs, shared by Mark Zaccardi on X, shows that “Nasdaq 100 EPS growth expected to be +43% this year,” comfortably beating the broader S&P 500 consensus of 24%.
While technical lines are fracturing in the near term, this stellar bottom-up earnings performance suggests that the current pullback may ultimately be a violent valuation reset rather than a structural bear market.
How Have Markets Performed In 2026?The S&P 500 index has advanced 7.23% year-to-date. Similarly, the Nasdaq Composite index was up 8.87%, and the Dow Jones gained 7.22% YTD.
The SPDR S&P 500 ETF Trust (NYSE:SPY) and QQQ, which track the S&P 500 and Nasdaq 100, respectively, closed lower on Friday. The SPY ended down 0.72% at $728.99, while the QQQ declined by 1.38% to $706.52.
Meanwhile, the Dow tracker, State Street SPDR Dow Jones Industrial Average ETF Trust (NYSE:DIA), closed 0.29% lower on Friday.
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo courtesy: JHVEPhoto via Shuttesstock
Market News and Data brought to you by Benzinga APIs
genedrive PLC (AIM:GDR, FRA:D6M) has signed a collaboration agreement with Thermo Fisher Scientific, sending its shares up 8% to 1.4p.
The point-of-care pharmacogenetic testing company will develop a high-throughput laboratory test under the deal.
The new test detects variants in the CYP2C19 gene, which influences how patients respond to the antiplatelet drug clopidogrel after a stroke.
It will be designed to run on Thermo Fisher's QuantStudio 5 Dx real-time PCR laboratory platform.
The collaboration gives genedrive access to a large global installed base of laboratory diagnostic machines, opening up a new market segment.
The kit targets centralised, high-throughput laboratory testing, addressing a different segment to the company's existing rapid, near-patient test.
Together, the two products position genedrive to serve both decentralised and laboratory-based testing pathways.
The new kit is on track for UK certification around the end of 2026, initially targeting the NHS genomic laboratory market.
Testing to guide clopidogrel use after stroke is recommended by health watchdog NICE, which supports laboratory-based genotyping.
The company highlighted a sizeable opportunity, with around 100,000 new stroke patients in the UK each year and 94 million people living with the effects of stroke globally.
Chief executive Gino Miele said the deal expanded genedrive's offering into the high-throughput market while complementing its established point-of-care solution.
Broadcom stock NASDAQ:AVGO has fallen sharply from its record high, but the selloff may say more about investor expectations than about weakness in AI demand.
Shares have retreated from around $495 to much lower levels, leaving the stock more than 24% below its peak.
That looks brutal, but Broadcom’s latest quarter was not a demand collapse. The company reported record revenue, strong earnings and a huge jump in AI semiconductor sales.
Broadcom’s fiscal second-quarter numbers were strong on the surface.
Revenue rose 48% from a year earlier to a record $22.2 billion, while adjusted earnings came in at $2.44 a share. AI semiconductor revenue jumped 143% year on year to $10.8 billion.
The real trigger was guidance. Broadcom said it expects AI chip revenue of about $16 billion in the fiscal third quarter.
That would still be more than triple the year-earlier level, but it came in below the roughly $17 billion-plus investors had hoped for.
The bigger disappointment was that CEO Hock Tan did not raise Broadcom’s longer-term AI target. He reiterated that the company is still aiming for more than $100 billion in AI chip sales in fiscal 2027.
In this market, “on track” was not enough.
Trading volume surged as the stock fell, showing this was a panic-style reset rather than a slow reassessment.
Broadcom’s management still sounds confident about demand.
Tan said demand for XPUs and networking is “simply insatiable,” adding that AI semiconductor bookings in the quarter were over $30 billion against the $10.8 billion the company shipped.
That means customers are still ordering far more than Broadcom can currently deliver.
The company has also pointed to gigawatt-scale commitments from major AI customers, including Anthropic, OpenAI and Meta.
Broadcom now expects to ship more than 10 gigawatts of AI chips in 2027, slightly above its earlier view.
Wall Street has not abandoned the stock either. JPMorgan reiterated its Overweight rating and $580 price target, telling clients it would be “aggressive buyers” at current levels.
The broader analyst picture remains heavily bullish. Recent consensus screens show dozens of Buy ratings, only a handful of Holds and no Sells, with average price targets still above $500.
There are real risks as CFO Kirsten Spears has previously flagged margin pressure as AI becomes a bigger part of Broadcom’s mix, because some AI system sales may carry lower margins than its software business.
Tan has also acknowledged that Google may diversify TPU suppliers over time, even though Broadcom remains central to Google’s custom chip roadmap.
Broadcom’s drop did not happen in isolation.
The selloff spilled into the broader semiconductor space, with Nvidia, AMD, Marvell, Intel, Micron and other chip names also coming under pressure in the days after the report.
Texas Instruments and Analog Devices were hit in a wider chip-sector pullback as investors questioned whether AI-related valuations had run too far.
The market was looking for any sign that the AI trade had become too crowded.
Broadcom’s decision not to raise its long-term target gave investors an excuse to take profits across the group.
, /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against ZoomInfo Technologies Inc. ("ZoomInfo" or "the Company") (NASDAQ: GTM) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Investors who purchased the Company's securities between November 3, 2025 and May 11, 2026, inclusive (the "Class Period"), are encouraged to contact the firm before August 24, 2026.
If you are a shareholder who suffered a loss, click here to participate.
We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at [email protected].
The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.
According to the Complaint, the Company made false and misleading statements to the market. ZoomInfo led investors to believe that it was enjoying growth in both legacy products and AI-driven innovations. The Company's growth plan did not mirror the reality of weakening demand. Based on these facts, the Company's public statements were false and materially misleading throughout the class period. When the market learned the truth about ZoomInfo, investors suffered damages.
Join the case to recover your losses
The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
CONTACT:
The Schall Law Firm
Brian Schall, Esq.,
www.schallfirm.com
Office: 310-301-3335
[email protected]
, /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against ZoomInfo Technologies Inc. ("ZoomInfo" or "the Company") (NASDAQ: GTM) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Shareholders who purchased shares of GTM during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments. Appointment as lead plaintiff is not required to partake in any recovery.
CLASS PERIOD: November 3, 2025 to May 11, 2026
DEADLINE: August 24, 2026
CASE DETAILS: According to the Complaint, the Company made false and misleading statements to the market. ZoomInfo made optimistic projections about the growth of its AI-powered products, but in reality faced customers revising purchase decisions and developing their own in-house AI solutions. Based on these facts, ZoomInfo's public statements were false and materially misleading throughout the class period.
If you are a shareholder who suffered a loss, contact us to participate.
WHY DJS LAW GROUP? DJS Law Group's primary focus is to enhance investor return through balanced counseling and aggressive advocacy. We specialize in securities class actions, corporate governance litigation, and domestic/international M&A appraisals. Our clients are some of the largest and most sophisticated hedge funds and alternative asset managers in the world. The litigation claims of our clients are extraordinarily valuable assets that demand respect, focus, and results.
Join the case to recover your losses.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
CONTACT:
David J. Schwartz
DJS Law Group
274 White Plains Road, Suite 1
Eastchester, NY 10709
Phone: 914-206-9742
Email: [email protected]
, /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Zoetis Inc. ("Zoetis" or "the Company") (NYSE: ZTS) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Investors who purchased the Company's securities between January 14, 2025 and May 6, 2026, inclusive (the "Class Period"), are encouraged to contact the firm before July 27, 2026.
If you are a shareholder who suffered a loss, click here to participate.
We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at [email protected].
The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.
According to the Complaint, the Company made false and misleading statements to the market. Zoetis suffered from weakening veterinarian prescription growth for its Librela medication after the FDA issued safety warnings about neurological complications in dogs. The Company's Trio product lost market share to competitors. The Company's Apoquel and Cytopoint dermatology products lost market share to newly launched competing treatments for dogs. Based on these facts, the Company's public statements were false and materially misleading throughout the class period. When the market learned the truth about Zoetis, investors suffered damages.
Join the case to recover your losses
The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
CONTACT:
The Schall Law Firm
Brian Schall, Esq.,
www.schallfirm.com
Office: 310-301-3335
[email protected]
, /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Zoetis Inc. ("Zoetis" or "the Company") (NYSE: ZTS) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Shareholders who purchased shares of ZTS during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments. Appointment as lead plaintiff is not required to partake in any recovery.
CLASS PERIOD: January 14, 2025 to May 6, 2026
DEADLINE: July 27, 2026
CASE DETAILS: According to the Complaint, the Company made false and misleading statements to the market. Zoetis faced challenges in multiple product lines including Librela, Apoquel, and Cytopoint. Based on these facts, Zoetis' public statements were false and materially misleading throughout the class period.
If you are a shareholder who suffered a loss, contact us to participate.
WHY DJS LAW GROUP? DJS Law Group's primary focus is to enhance investor return through balanced counseling and aggressive advocacy. We specialize in securities class actions, corporate governance litigation, and domestic/international M&A appraisals. Our clients are some of the largest and most sophisticated hedge funds and alternative asset managers in the world. The litigation claims of our clients are extraordinarily valuable assets that demand respect, focus, and results.
Join the case to recover your losses.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
CONTACT:
David J. Schwartz
DJS Law Group
274 White Plains Road, Suite 1
Eastchester, NY 10709
Phone: 914-206-9742
Email: [email protected]
Consumers managing their finances through digital channels increasingly assume that money will appear in accounts quickly, with visibility into when it can be used.
For investment platforms, that expectation carries operational consequences. The pace of deposits and withdrawals influences how customers interact with brokerage services, whether they expand their activity across multiple products and how frequently they return to the platform.
Michael Silver, CTS partnerships lead at Robinhood, said quicker access to money has contributed to broader adoption of the company’s products. Customers who begin with a brokerage account often move into other offerings once money can be transferred in and out without extended delays, he said.
“We’ve seen users adopt more and more [offerings] within our ecosystem,” Silver said, adding that customers now use services ranging from brokerage accounts to custodial accounts that allow parents to begin building assets for their children.
That shift reflects a broader pattern across financial platforms. When users can move money easily between accounts and services, they tend to consolidate more of their financial activity within a single ecosystem.
The discussion took place as part of a PYMNTS series examining customer journeys enabled through Visa Direct, with a focus on how faster fund flows affect engagement across digital financial services.
The Importance of Speed on Investment Platforms Speed has become a central concern for investors who manage their finances through mobile platforms. Robinhood customers expect to move money into accounts, place trades and withdraw money without prolonged waiting periods.
“Speed and security moving funds through our platform” are among the main priorities for users, Silver said, because available funds determine whether investors can participate in trading activity or shift money between financial products.
Robinhood offers several options that allow users to choose how they transfer money. Real-time money movement methods such as card-based transactions complement older mechanisms, such as automated ACH transfers and wires.
The objective is not to eliminate traditional payment channels but to provide customers with multiple ways to move money depending on the urgency of the transaction and the type of account involved, he said.
That flexibility has become increasingly important as the platform expands beyond retail brokerage into additional financial services, including retirement accounts and family-oriented investment tools.
Headwinds Facing Fast Money Movement The shift toward faster payments comes with natural growing pains. The brokerage sector operates within regulatory frameworks that require careful monitoring of transactions and adherence to evolving compliance standards.
Robinhood’s approach to fast money movement helps distinguish the company from more traditional brokerages, Silver said.
“We’re definitely pushing the envelope in the brokerage space,” he said, adding that some institutions remain cautious about offering certain real-time capabilities because of operational and compliance concerns.
Cybersecurity pressures also influence how quickly financial platforms adopt new payment methods. Firms must evaluate fraud risk, monitor transaction activity and maintain safeguards while still providing the speed that customers expect.
Funding Accounts and Cashing Out Deposits and withdrawals remain among the most visible elements of the customer experience. Delays associated with traditional payment rails can create uncertainty for investors who are waiting for funds to arrive, Silver said.
“There’s nothing worse than doing a withdrawal through a bank and having to wait two, four or five days for it to settle,” he said.
That uncertainty can affect how customers use the platform. Investors may postpone trades or delay financial decisions while they wait for transfers to clear.
Fast payment options address part of that concern by providing clearer timelines for when funds will become available. For some customers, the ability to move money quickly allows them to respond to changes in financial markets or handle routine expenses without moving funds through multiple accounts.
The Mechanics Behind Fund Flows The user experience on an investment platform rests on a complex infrastructure that coordinates several payment channels simultaneously.
Brokerages must manage transfers between bank accounts, card networks and internal settlement systems. In some situations, platforms allow customers to use money before the underlying transaction has fully settled, which requires careful risk management.
Real-time payment rails help narrow the time between the initiation of a transfer and the moment funds become available to the user, Silver said.
“The real-time payments close the gap versus a traditional ACH deposit or transfer,” he said, adding that card-based payments allow money to be accessed quickly even when settlement occurs later.
Faster payments also influence how platforms manage liquidity. Financial institutions must balance the need to provide immediate access to money with the operational realities of settlement timelines.
Fast payment rails provide a way to improve liquidity management by accelerating the movement of cash through the platform, Silver said.
“Every business wants to have as much cash on hand as possible,” he said, adding that faster payment rails enable money to circulate more quickly than traditional transfer methods.
Working With Partners to Move Money Delivering real-time payments requires coordination between financial platforms, payment networks and issuing banks.
Robinhood works with partners to ensure that payments data moves through the system accurately and in compliance with network requirements, Silver said. Clear transaction information helps financial institutions verify transfers and reduces friction in the payment process.
Maintaining those standards is increasingly important as platforms expand their product offerings and the volume of transactions increases.
Balancing Speed and Security The pursuit of faster fund flows must be accompanied by strong safeguards. The balance between speed and security depends on the quality of data associated with each transaction, Silver said.
Robinhood’s collaboration with Visa Direct illustrates how payment networks contribute to fast money movement.
Card-based payment rails provide a familiar and widely accessible method for customers to transfer money between bank accounts and investment platforms, he said.
“Visa Direct definitely provides the easiest flexibility for all of our users,” Silver said, adding that the system allows customers to move money between accounts in near real time. Because most customers already hold debit or credit cards, card networks provide a convenient bridge between traditional bank accounts and digital financial platforms.
The result of these changes is a different experience for investors.
“Having the clear line of sight of where the funds are and when they’re going to be available is very important for our users,” Silver said.
Actual fund availability for all Visa Direct transactions may depend on receiving financial institution, account type, region and compliance processes, along with other factors, as applicable.
SummaryFourth VLCC loading at Ras Tanura on Monday -dataIran increases oil loadings at Kharg Island -WindwardTwo VLCCs head to UAE port for loading -dataQatar, ADNOC LNG tankers head to India, China -dataSINGAPORE, June 29 (Reuters) - Middle East producers are pushing ahead with loading oil and liquefied natural gas despite fresh ship attacks in the Strait of Hormuz and renewed strikes between the U.S. and Iran in recent days, shipping data showed.
Energy shipping in the strait slowed after attacks on a container ship on Thursday and an oil tanker on Saturday sparked fresh tit-for-tat strikes, straining Washington and Iran's interim peace deal.
The Reuters Power Up newsletter provides everything you need to know about the global energy industry. Sign up here.
But on Sunday, a U.S. official said the two countries had agreed to halt recent hostilities and renew talks over the strategically important waterway.
On Monday, a fourth Very Large Crude Carrier, capable of carrying 2 million barrels of oil, was seen loading at Saudi Arabia's Ras Tanura terminal, LSEG data showed, even after a helicopter belonging to the company crashed on Sunday, killing 14 people. The cause of the crash was unknown.
Three other VLCCs have loaded oil and gone dark since leaving the terminal over the weekend, according to the data. Going dark refers to vessels with their transponders switched off to reduce the risk of attack while sailing through the Gulf.
One of these supertankers emerged on Monday, having exited the strait, and is now heading for Japan, the data showed.
Two VLCCs entered the strait on Sunday and have docked at a United Arab Emirates terminal to load crude, LSEG data showed.
Saudi Aramco declined to comment.
The Abu Dhabi National Oil Co said the company does not comment on the position, movements and routing of its vessels as a matter of policy.
IRAN ACCELERATES OIL LOADINGSIran is also accelerating oil loadings after Washington waived sanctions on its exports for 60 days.
Tehran loaded simultaneously at both of its export terminals at Kharg Island on Saturday for the first time in nearly a week, according to maritime intelligence firm Windward.
Kpler data showed Iranian-flagged VLCCs Dan and Hawk, entered the strait on Saturday, while about 8 million barrels of Emirati and Qatari crude moved out on four VLCCs during the weekend. The National Iranian Oil Co could not be immediately reached for comment.
Rising exports from the Gulf, a region that accounts for a third of the world's oil supplies, are sending global oil prices lower, with Brent down 10.6% last week, its third weekly decline, although the fresh weekend strikes lifted prices on Monday.
"If you take the view that the Strait will continue with an uneven re-opening in the weeks and months ahead, then crude oil right here is reasonably priced with a downward bias," said IG markets analyst Tony Sycamore.
"However, if you feel the risks are that one of these weekend flare-ups leads to the conflict re-igniting more broadly then crude oil prices here are just way too cheap."
QATAR, UAE CONTINUE LNG EXPORTSOn liquefied natural gas, two additional ballast tankers appeared on ship-tracking data in the west of the strait on June 26 after going dark, while two other loaded LNG tankers have exited Hormuz.
The Al Kharaitiyat is heading to Kuwait after loading at Qatar's Ras Laffan terminal while another QatarEnergy-controlled vessel, the Al Kharsaah, is waiting off Qatar, Kpler ship-tracking data showed.
Meanwhile, the ADNOC-controlled Mraweh, which loaded at UAE's Das Island on June 21, is scheduled to deliver its cargo to the Dahej terminal on India's west coast on July 5, according to Kpler data. Al Hamla, controlled by QatarEnergy, transporting a cargo loaded at Ras Laffan on June 18, is scheduled to reach China on July 3, LSEG and Kpler data showed.
QatarEnergy did not immediately respond to an email seeking comment.
Reporting by Florence Tan and Emily Chow; Editing by Kate Mayberry
Our Standards: The Thomson Reuters Trust Principles., opens new tab
, /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Commvault Systems, Inc. ("Commvault" or "the Company") (NASDAQ: CVLT) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Shareholders who purchased shares of CVLT during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments. Appointment as lead plaintiff is not required to partake in any recovery.
CLASS PERIOD: April 29, 2025 to January 26, 2026
DEADLINE: July 17, 2026
CASE DETAILS: According to the Complaint, the Company made false and misleading statements to the market. Commvault touted its ARR growth while disregarding important factors such as type of sale when developing its growth guidance. Based on these facts, Commvault's public statements were false and materially misleading throughout the class period.
If you are a shareholder who suffered a loss, contact us to participate.
WHY DJS LAW GROUP? DJS Law Group's primary focus is to enhance investor return through balanced counseling and aggressive advocacy. We specialize in securities class actions, corporate governance litigation, and domestic/international M&A appraisals. Our clients are some of the largest and most sophisticated hedge funds and alternative asset managers in the world. The litigation claims of our clients are extraordinarily valuable assets that demand respect, focus, and results.
Join the case to recover your losses.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
CONTACT:
David J. Schwartz
DJS Law Group
274 White Plains Road, Suite 1
Eastchester, NY 10709
Phone: 914-206-9742
Email: [email protected]
A 3D printed DNA Helix model and word "DNA" are seen in this illustration taken February 4, 2026. REUTERS/Dado Ruvic/Illustration Purchase Licensing Rights, opens new tab
CompaniesLONDON/ZURICH, June 29 (Reuters) - Swiss pharma and diagnostics giant Roche on Monday launched its long-awaited Axelios gene sequencer, in a bid to challenge U.S. firm Illumina's (ILMN.O), opens new tab leadership in next-generation sequencing.
Roche's launch is limited to academic and research-focused facilities and comes more than a decade after the group's failed $6.8 billion hostile bid to acquire Illumina.
Jumpstart your morning with the latest legal news delivered straight to your inbox from The Daily Docket newsletter. Sign up here.
The Axelios platform is designed to rapidly read and analyse DNA at scale, supporting applications from disease research to drug development.
Analysts say Roche's entry is likely to be a gradual push for market share rather than a rapid disruption of the sector, which is valued at about $7.3 billion. Illumina remains the clear leader, with estimates putting its share of NGS systems at around 70%.
Roche said it aims to place about 100 machines in the first year, a target that will lay the foundation for a future "blockbuster" franchise generating over 1 billion Swiss francs ($1.1 billion) in annual sales over the long term.
The company has partnered with 10x Genomics (TXG.O), opens new tab and Google (GOOGL.O), opens new tab DeepVariant for data analysis, backed by early platform validation from Broad Clinical Labs and the Hartwig Medical Foundation to ease adoption.
Roche said it has already begun commercial shipments and booked pre-orders. The launch is focused on U.S., UK, Germany, France, among others and Roche expects to quickly expand into other geographies.
Reporting by Bhanvi Satija in London and Marleen Kaesebier in Zurich, Editing by Louise Heavens
Our Standards: The Thomson Reuters Trust Principles., opens new tab
Bhanvi is a London-based reporter covering European pharmaceutical companies and the healthcare industry. She previously covered U.S. health and pharma firms, with a focus on the new weight loss drugs that are transforming the obesity treatment space. Her coverage includes a trend piece on the underuse of their weight-loss drugs among men, increased interest in therapies being developed for preservation of lean mass, and a scoop on gene therapy maker Sarepta defying an FDA order to stop shipping its muscular dystrophy treatment.
Marleen is a company correspondent based in Zurich where she covers the likes of Swiss pharma and insurance. Previously, she wrote about Swiss and German markets as a news reporter and graduated from the Columbia Journalism School.
EverCommerce (EVCM) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
, /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Peabody Energy Corporation ("Peabody" or "the Company") (NYSE: BTU) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Investors who purchased the Company's securities between October 14, 2024 and May 4, 2026, inclusive (the "Class Period"), are encouraged to contact the firm before August 24, 2026.
If you are a shareholder who suffered a loss, click here to participate.
We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at [email protected].
The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.
According to the Complaint, the Company made false and misleading statements to the market. Peabody falsely led investors to believe it could reliably predict the ramp-up and growth of its Centurion mine. The Company suffered wide-ranging issues and delays at the Centurion mine. Based on these facts, the Company's public statements were false and materially misleading throughout the class period. When the market learned the truth about Peabody investors suffered damages.
Join the case to recover your losses
The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
CONTACT:
The Schall Law Firm
Brian Schall, Esq.,
www.schallfirm.com
Office: 310-301-3335
[email protected]
